Methods and kits are disclosed for use in the analysis of microsatellite instability in genomic DNA. Methods and kits are also disclosed which can be used to detect microsatellite instability DNA present in biological materials, such as tumors. The methods and kits of the present invention can be used to detect or diagnose diseases associated with microsatellite instability, such as certain types of cancer.
FIG. 1

Allele 1

Allele 2

Normal

Tumor

PCR

Size Separation by CE

MSI
FIG. 2

- Mononucleotide
- Dinucleotide
- Trinucleotide
- Tetranucleotide
- Pentanucleotide
Low Stutter Tetra-nucleotide vs. High Stutter Di-nucleotide

Normal #1a vs. Normal #1b

Tumor #1a vs. Tumor #1b

Normal #2a vs. Normal #2b

Tumor #2a vs. Tumor #2b

FIG. 3
FIG. 4
FIG. 5
FIG. 6
FIG. 7
FIG. 8
FIG. 10
FIG. 11
FIG. 12
FIG. 15

GenScan™ Project-4/15/01 Display-4
FIG. 16
DETECTION OF MICROSATELLITE INSTABILITY AND ITS USE IN DIAGNOSIS OF TUMORS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 09/663,020, filed Sep. 15, 2000.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made using U.S. government Small Business Innovation Research Program Grant CA76834-02 from the National Institutes of Health. The U.S. government retains certain rights to the invention.

TECHNICAL FIELD OF THE INVENTION

This invention relates to the detection of instability in regions of genomic DNA containing simple tandem repeats, such as microsatellite loci. The invention particularly relates to multiplex analysis for the presence or absence of instability in a set of microsatellite loci in genomic DNA from cells, tissue, or bodily fluids originating from a tumor. The invention also relates to the use of microsatellite instability analysis in the detection and diagnosis of cancer and predisposition for cancer.

BACKGROUND OF THE INVENTION

Microsatellite loci of genomic DNA have been analyzed for a wide variety of applications, including, but not limited to, paternity testing, forensics work, and in the detection and diagnosis of cancer. Cancer can be detected or diagnosed based upon the presence of instability at particular microsatellite loci that are unstable in one or more types of tumor cells.

A microsatellite locus is a region of genomic DNA with simple tandem repeats that are repetitive units of one to five base pairs in length. Hundreds of thousands of such microsatellite loci are dispersed throughout the human genome. Microsatellite loci are classified based on the length of the smallest repetitive unit. For example, loci with repetitive units of 1 to 5 base pairs in length are termed “mononucleotide”, “dinucleotide”, “trinucleotide”, “tetranucleotide”, and “pentanucleotide” repeat loci, respectively.

Each microsatellite locus of normal genomic DNA for most diploid species, such as genomic DNA from mammalian species, consists of two alleles at each locus. The two alleles can be the same or different from one another in length and can vary from one individual to the next. Microsatellite alleles are normally maintained at constant length in a given individual and its descendents; but, instability in the length of microsatellites has been observed in some tumor types (Aaltonen et al., 1993, Science 260:812-815; Thibodeau et al., 1993 Science 260:816-819; Peltoniemi et al., 1993 Cancer Research 53:5853-5855; Ionov et al., 1993 Nature 363:558-561). This form of genomic instability in tumors, termed microsatellite instability (hereinafter, “MSI”), is a molecular hallmark of the inherited cancer syndrome Hereditary Nonpolyposis Colorectal Cancer (hereinafter, “HNPCC”). The cause of MSI in HNPCC is thought to be a dysfunctional DNA mismatch repair system that fails to reverse errors that occur during DNA replication (Fisher et al., 1993 Cell 75:1027-38; Leach et al., 1993 Cell 75:215-25; Bronner et al., 1994 Nature 368:258-61; Nicolaides et al., 1994 Nature 371:75-80; Miyaki et al., 1997 Nat Genetics 17:271-2). Insertion or deletion of one or more repetitive units during DNA replication persists without mismatch repair and can be detected as length polymorphisms by comparison of allele sizes found in microsatellite loci amplified from normal and tumor DNA samples (Thibodeau et al., 1993, supra).

MSI has been found in over 90% of HNPCC and in 10-20% of sporadic colorectal tumors (Liu et al., 1996 Nature Med 2:169-174; Thibodeau et al., 1993, supra; Ionov et al., 1993 Nature 363:558-561; Aaltonen et al., 1993 Science 260:812-816; Lothe et al., 1993 Cancer Res. 53:5849-5852). However, MSI is not limited to colorectal tumors. MSI has also been detected in pancreatic cancer (Han et al., 1993 Cancer Res 53:5087-5089) gastric cancer (Id.; Peltoniemi et al., 1993 Cancer Res 53:5853-5855; Mironov et al., 1994 Cancer Res 54:41-44; Ryu et al., 1994 Oncogene 9:29-32; Chong et al., 1994 Cancer Res 54:4595-4597), prostate cancer (Gao et al., 1994 Oncogene 9:2999-3003), endometrial cancer (Risinger et al., 1993 Cancer Res 53:5100-5103; Peltoniemi et al., 1993 Cancer Res 53:5853-5855), and breast cancer (Patel et al., 1994 Oncogene 3:3695-3700). The genetic basis of HNPCC is thought to be a germ-line mutation in one of several DNA mismatch repair genes (hereinafter “MMR”) (Leach et al., 1993 Cell 75:1215-1225; Fishel et al., 1993 Cell 75:1027-38; Leach et al., 1993 Cell 75:215-25; Bronner et al., 1994 Nature 368:258-61; Nicolaides et al., 1994 Nature 371:75-80; Miyaki et al., 1997 Nat Genetics 17:271-2; Papadopoulos et al., 1994 Science 263:1625-1629) Among HNPCC patients, 50-60% have been reported to carry inherited mutations in two mismatch repair genes, MSH2 and MLH1 (Kolodner et al., 1999 Cancer Research 59:5068-5074). Moreover, 70-100% of HNPCC cases whose tumors manifest a high frequency MSI (hereinafter “MSI-H”) phenotype reportedly have germ-line mutations in these two genes. Few germ-line mutations in MSH6, MSH3, PMS1 and PMS2 genes have been reported in HNPCC patients, indicating that inherited mutations in these mismatch repair genes play a minor role in HNPCC (Peltoniemi et al., 1997 Gastroenterology 113:1146-1158; Liu et al., 1996 Nat Med 2:169-174; Kolodner et al., 1999 Cancer Research 59:5068-5074). Without functional repair proteins, errors that occur during replication are not repaired leading to high mutation rates and increased likelihood of tumor development.

Repetitive DNA is particularly sensitive to errors in replication and therefore dysfunctional mismatch repair systems result in widespread alterations in microsatellite regions. A study of yeast cells without functional mismatch repair systems showed a 2800, 284, 52, and 19 fold increase in mutation rates in mono-, di-, tri-, tetra-, and pentanucleotide repeats, respectively (Sia et al., 1997 Molecular and Cellular Biology 17:2851-2858). Mutations in mismatch repair genes are not thought to play a direct role in tumorigenesis, but rather act by allowing DNA replication errors to persist. Mismatch repair deficient cells have high mutation rates and if these mutations occur in genes involved in tumorigenesis the result can lead to the development of cancer. MSI positive tumors have been found to carry somatic frameshift mutations in mononucleotide repeats in the coding region of several genes involved in growth
control, apoptosis, and DNA repair (e.g., TGFBR1, BAX, IGFIIR, TCF4, MSH3, MSH6) (Planck et al., 2000 Genes, Chromosomes & Cancer 29:33-39; Yamamoto et al., 1998 Cancer Research 58:997-1003; Grady et al., 1999 Cancer Research 59:320-324; Markowitz et al., 1995 Science 268:1336-1338; Parsons et al., 1995 Cancer Research 55:5548-5550). The most commonly altered locus is TGFBR1, in which over 90% of MSI-H colon tumors have been found to contain a mutation in the 10 base polyadenine repeat present in the gene (Markowitz et al., 1995 Science 268:1336-1338).

[0010] MSI occurs in almost all HNPPC tumors regardless of which mismatch repair gene is involved. MSI has also been shown to occur early in tumorigenesis. These two factors contribute to making MSI analysis an excellent diagnostic test for the detection of HNPPC. In addition, MSI analysis can serve as a useful pre-screening test to identify potential HNPPC patients for further genetic testing. MSI analysis of sporadic colorectal carcinomas is also desirable, since the occurrence of MSI correlates with a better prognosis (Bertario et al., 1999 International J Cancer 80:83-7).

[0011] One long-standing problem with diagnosing HNPPC is that colon tumor biopsies from a person with HNPPC look the same pathologically as a sporadic colon tumor, making diagnosis of the syndrome difficult. Since prognosis, therapy and follow-up will be different for patients with HNPPC, it is important to find more definitive diagnostic methods. However, mutation detection in HNPPC patients remains difficult because there are at least 5 known MMR genes which are large genes without known hot spots for mutations. Direct gene sequencing remains the most precise method of mutation detection, but is time consuming and expensive (Terdiman et al., 1999 The American Journal of Gastroenterology 94:2354-2356). In addition, high sensitivity and specificity can be difficult to obtain with sequencing alone because many mutations that are detected may be harmless polymorphisms that have no affect on the function of the mismatch repair proteins.

[0012] DNA analysis of microsatellite loci makes it theoretically possible to develop a blood test for use in the detection of specific types of cancer. Early studies have shown that tumor DNA is released into the circulation, and is present in particular high concentrations in plasma and serum in a number of different types of cancer (Leon et al., 1977 Cancer Res 37:646-650; Sironi et al., 1989 Oncology 46:318-322). Since then, DNA released into the blood from several different types of tumors has been detected by analysis of microsatellite DNA using the polymerase chain reaction (hereinafter, “PCR”) (Hibi et al., 1998 Cancer Research 58:1405-1407; Chen et al., 1999 Clinical Cancer Research 5:2297-2303; Kopreski et al., 1999 Clinical Cancer Research 5:1961-1965; Fujiwara et al., 1999 Cancer Research 59:1567-1571; Chen et al., 1996 Nature Medicine 2:1033-1034; Goessl et al., 1998 Cancer Research 58:4728-4732; Miozzi et al., 1996 Cancer Research 56:2285-2288).

[0013] The first tumor-specific gene sequences detected in blood from patients with cancer were mutated K-ras genes (Vasishtkhin et al., 1994 Br J Haematol 86: 774-779; Sorenson et al., 1994 Br J Haematol 86: 774-779; Sorenson et al., 2000 Clinical Cancer Research 6:2129-2137; Anker et al., 1997 Gastroenterology 112:1114-1120). More recently, detection of microsatellite instability in soluble tumor DNA from plasma and serum originating from head and neck squamous cell cancers (Nawroz et al., 1996 Nature Med 2:1035-1037) and small cell lung cancers (Chen et al., 1996 Nature Med 2:1033-1035) has been shown. These successes have stimulated searches for microsatellite instability in circulating tumor DNA from many other cancer types. Hibi et al., used microsatellite markers to search for the presence of genetic alterations in serum DNA from colon cancer patients (Hibi, K. et al., 1998 Cancer Research 58:1405-1407). Hibi et al., also reported that eighty percent of primary tumors in the colon cancer patients displayed MSI and/or loss of heterozygosity (hereinafter, “LOH”), another type of mutation discussed below. No microsatellite or LOH mutations were detected in paired serum DNA. However, identical K-ras mutations were found in corresponding tumor and serum DNAs, indicating that tumor DNA was present in the blood. (Id.)

[0014] The detection of circulating tumor cells and micrometastases may also have important prognostic and therapeutic implications. Because disseminated tumor cells are present in very small numbers, they are not easily detected by conventional immunocytochemical tests, which can only detect a single tumor cell among 10,000 to 100,000 normal cells (Ghoussein et al., 1999 Clinical Cancer Research 5:1950-1960). More sensitive molecular techniques based on PCR amplification of tumor-specific abnormalities in DNA or RNA have greatly facilitated detection of occult (hidden) tumor cells. PCR-based tests capable of routinely detecting one tumor cell in one million normal cells have been devised for identification of circulating tumor cells and micrometastases in leukemias, lymphomas, melanoma, neuroblastoma, and various types of carcinomas. (Id.)

[0015] Most targets for detection of disseminated tumor cells have been mRNAs. However, some DNA targets have been used successfully, including K-ras mutations in colon cancers, as noted above. The presence of microsatellite instability in some types of tumor cells raises the possibility that these tumor specific mutations created by the instability could serve as a target for PCR-based detection of occult tumor cells.

[0016] There has been considerable controversy about how to precisely define and accurately measure MSI (Boland, 1998 Cancer Research 58:5248-5257). Reports on the frequency of MSI in various tumors ranges considerably. For example, different studies have reported ranges of 3% to 95% MSI for the frequency of MSI in bladder cancer (Gonzalez-Zaleta et al., 1993 Cancer Research 53:28-30; Mao et al., 1996 PNAS 91:9871-9875). One problem with defining MSI is that it is both tumor specific and locus dependent (Boland et al. 1998, supra). Thus, the frequency of MSI observed with a particular tumor type in a single study will depend on the number of tumors analyzed, the number of loci investigated, how many loci need to be altered to score a tumor as having MSI and which particular loci were included in the analysis. To help resolve these problems, the National Cancer Institute sponsored a workshop on MSI to review and unify the field (Id.). As a result of the workshop, a panel of five microsatellites was recommended as a reference panel for future research in the field. This panel included two mononucleotide loci BAT-25, BAT-26, and three dinucleotide loci DSS346, D2S123, D17S250.
One particular problem in MSI analysis of tumor samples occurs when one of the normal alleles for a given marker is missing due to LOH, and no other novel fragments are present for that marker (Id.). One cannot easily discern whether this represents true LOH or MSI in which the shifted allele has co-migrated with the remaining wild-type allele. In cases like this, the recommendation from the NCI workshop on MSI was not to call it as MSI. One way to minimize this type of problem would be to use loci that displayed low frequency of LOH in colon tumors.

Clinical diagnostic assays used for determining treatment and prognosis of disease require that the tests be highly accurate (low false negatives) and specific (low false positive rate). Many informative microsatellite loci have been identified and recommended for MSI testing (Boland et al. 1998, supra). However, even the most informative microsatellite loci are not 100% sensitive and 100% specific. To compensate for the lack of sensitivity using individual markers, multiple markers can be used to increase the power of detection. The increased effort required to analyze multiple markers can be offset by multiplexing. Multiplexing allows simultaneous amplification and analysis of a set of loci in a single tube and can often reduce the total amount of DNA required for complete analysis. To increase the specificity of an MSI assay for any given type of cancer, it has been recommended that the panel of five highly informative microsatellite loci identified at the National Institute Workshop (see above) be modified to substitute or add other loci of equal utility (Boland et al. 1998, supra, at p. 5250). Increased information yielded from amplifying and analyzing greater numbers of loci results in increased confidence and accuracy in interpreting test results.

Multiplex MSI analysis solves problems of accuracy and discrimination of MSI phenotypes, but the additional complexity can make analysis more challenging. For example, when microsatellite loci are co-amplified and analyzed in a multiplex format, factors affecting ease and accuracy of data interpretation become much more essential. One of the primary factors affecting accurate data interpretation is the amount of stutter that occurs at microsatellite loci during PCR (Bacher & Schumm, 1998 Profiles in DNA 2:3-6; Perucchio, 1999 Cancer Research 59:249-256). Stutter products are minor fragments produced by the PCR process that differ in size from the major allele by multiples of the core repeat unit. The amount of stutter observed in microsatellite loci tends to be inversely correlated with the length of the core repeat unit. Thus, stutter is most severely displayed with mono- and dinucleotide repeat loci, and to a lesser degree with tri-, tetra-, and pentanucleotide repeats (Bacher & Schumm, 1998, supra). Use of low stutter loci in multiplexes would greatly reduce this problem. However, careful selection of loci is still necessary in choosing low stutter loci because percent stutter can vary considerably even within a particular repeat type (Micka et al., 1999 Journal of Forensic Sciences 44:1-15).

Microsatellite multiplex systems have been primarily developed for use in genotyping, mapping studies and DNA typing applications. These multiplex systems are designed to allow co-amplification of multiple microsatellite loci in a single reaction, followed by detection of the size of the resulting amplified alleles. For DNA typing analysis, the use of multiple microsatellite loci dramatically increases the matching probability over a single locus. Matching probability is a common statistic used in DNA typing that defines the number of individuals you would have to survey before you would find the same DNA pattern as a randomly selected individual. For example, a four locus multiplex system (GenePrint™ CTV Multiplex System, Promega) has a matching probability of 1 in 252.4 in African-American populations, compared to an eight locus multiplex system (GenePrint™ PowerPlex™ 1.2 System, Promega) which has a matching probability of 1 in 2.74x10^8 (Proceedings: American Academy of Forensic Sciences (Feb. 9-14, 1998), Schumm, James W. et al., p. 53, B88; Id. Gibson, Sandra D. et al., p. 53, B89; Id., Lazaruk, Katherine et al., p. 51, B83; Sparkes, R. et al., 1996 Int J Legal Med 109:186-194). Other commercially available multiplex systems for DNA typing include AmpFISTR Profiler™ and AmpFISTR COfiler™ (AmpFISTR Profiler™ PCR Amplification Kit User’s Manual (1997), i-viii and 1-1 to 1-10; and AmpFISTR COfiler™ PCR Amplification Kit User Bulletin (1998), i-iii and 1-1 to 1-10, both published by Perkin-Elmer Corp.). In addition to multiplexes for DNA typing, a few multiplex microsatellite systems have been developed for the detection of diseases, such as cancer. One such system has been developed by Roche Diagnostics, the “HNPC Microsatellite Instability Test”, in which five MSI loci (BAT25, BAT26, D5S436, D17S250, and D2S123) are co-amplified and analyzed. Additional systems are needed, particularly systems that include additional loci displaying high sensitivity to MSI and low stutter for easy and accuracy of analysis.

The materials and methods of the present invention are designed for use in multiplex analysis of particular microsatellite loci of human genomic DNA from various sources, including various types of tissue, cells, and bodily fluids. The present invention represents a significant improvement over existing technology, bringing increased power of discrimination, precision, and throughput to the analysis of MSI loci and to the diagnosis of illness, such as cancer, related to mutations at such loci.

**BRIEF SUMMARY OF THE INVENTION**

The present invention provides methods and kits for amplifying and analyzing microsatellite loci or sets of microsatellite loci. The present invention also provides methods and kits for detecting cancer in an individual by co-amplifying multiple microsatellite loci of human genomic DNA originating from tumor tissue or cancerous cells.

In one aspect, the present invention provides a method of analyzing micro-satellite loci, comprising: (a) providing primers for co-amplifying in a single tube a set of at least three microsatellite loci of genomic DNA, comprising at least one mononucleotide repeat locus and at least two tetranucleotide repeat loci; (b) co-amplifying the set of at least three microsatellite loci from a sample of genomic DNA in a multiplex amplification reaction, using the primers, thereby producing amplified DNA fragments; and (c) determining the size of the amplified DNA fragments.

In another aspect, the present invention provides a method of co-amplifying the set of at least three microsatellite loci of at least two different samples of genomic DNA, a first sample originating from normal non-cancerous biological material from an individual and a second sample
originating from a second biological material from the individual. The at least two samples of human genomic DNA are co-amplified in separate multiplex amplification reactions, using primers to each of the loci in the set of at least three microsatellite loci. The size of the resulting amplified DNA fragments from the two multiplex reactions are compared to one another to detect instability in any of the at least three microsatellite loci of the second sample of human genomic DNA.

[0025] Another embodiment of the present invention is a method of analyzing at least one mononucleotide repeat locus of human genomic DNA selected from the group consisting of MONO-11 and MONO-15. The method of analyzing the at least one mononucleotide repeat locus selected from the group consisting of MONO-11 and MONO-15 comprises the steps of: (a) providing at least one primer of the at least one mononucleotide repeat locus; (b) amplifying the at least one mononucleotide repeat locus from a sample of genomic DNA originating from a biological material from an individual human subject, using the at least one primer, thereby producing an amplified DNA fragment; and (c) determining the size of the amplified DNA fragments. The amplified DNA fragments are preferably analyzed to detect microsatellite instability at the at least one mononucleotide repeat locus by comparing the size of the amplified DNA fragments to the most commonly observed allele size at that locus in a human population. Alternatively, the method is used to amplify the at least one mononucleotide repeat locus of a sample of human genomic DNA from normal non-cancerous biological material from an individual, and microsatellite instability is detected by comparing the resulting amplified DNA fragments to those obtained in step (b).

[0026] Another embodiment of the present invention is a kit for the detection of microsatellite instability in DNA isolated from an individual subject, comprising a single container with oligonucleotide primers for co-amplifying a set of at least three microsatellite loci comprising one mononucleotide locus and two tetranucleotide loci.

[0027] The various embodiments of the method and kit of the present invention, described briefly above, are particularly suited for use in the detection of MSI in tumor cells or cancerous cells. Specifically, the method or kit of the present invention can be used to amplify at least one mononucleotide repeat locus selected from the group consisting of MONO-11 and MONO-15 or the set of at least three microsatellite loci comprising at least one mononucleotide repeat locus and at least two tetranucleotide repeat loci of at least one sample of genomic DNA from biological material, such as tissue or bodily fluids, preferably biological material containing or suspected of containing DNA from tumors or cancerous cells. For monomorphic or quasi-monomorphic loci, such as MONO-11 and MONO-15, one can compare the resulting pattern to the pattern produced by amplifying normal DNA from any individual in a population with a standard pattern at that locus. However, it is preferable to use DNA from normal tissue of the same individual from whom the tumor DNA was obtained, in order to ensure that a positive result does not reflect a germline mutation, rather than MSI.

[0028] The method and kit can also be used to compare the results of multiplex amplification of DNA from normal tissue of an individual to the results of multiplex amplification of DNA from other biological material from the same individual. Use of this particular embodiment of the method of the present invention to detect MSI in tumor cells by comparison to normal cells is illustrated in FIG. 1. Specifically, FIG. 1 shows a tetranucleotide repeat (GATA), amplified by a primer pair ("primer A" and "primer B") in a polymerase chain reaction ("PCR"), followed by separation of amplified alleles by size using capillary electrophoresis, and a plot of the fractionated amplified alleles using GeneScan™ software. Note that only the two alleles and small stutter peaks appear in the plot of amplified DNA from normal DNA, while three MSI peaks appear in addition to the two allele peaks in the plot of amplified tumor DNA.

[0029] Advantages and a fuller appreciation of the specific attributes of this invention will be gained upon an examination of the following figures, detailed description of preferred embodiments, and appended claims. It is expressly understood that the drawings are for the purposes of illustration and description only, and are not intended as a definition of the limits of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0030] FIG. 1. Illustration of microsatellite instability analysis. The figure is a diagram of a primer pair annealed to a tetranucleotide locus on two alleles of the same genomic DNA, and plots of results of capillary electrophoresis of products of amplification of a tetranucleotide locus of DNA originating from normal vs. tumor tissue. MSI peaks are indicated in the plot of amplified DNA from tumor tissue.

[0031] FIG. 2. Illustration of effect of microsatellite repeat unit length on amount of stutter observed. The figure includes a diagram of a primer pair annealed to a tetranucleotide repeat locus on two different alleles of genomic DNA, and a set of fluorescent scans and plots of amplified mono-, di-, tri-, tetra-, and pentanucleotide repeat loci from human genomic DNA from various individuals, amplified and fractionated by gel or by capillary electrophoresis.

[0032] FIG. 3. Demonstration that low stutter tetranucleotide repeat loci are easier to interpret than high stutter dinucleotide repeat loci. The figure is a plot of results of capillary electrophoresis of products of the amplification of two tetranucleotide and two dinucleotide repeat loci of two different sets of samples of DNA originating from normal vs. tumor tissue.

[0033] FIG. 4. Illustration of variance in amount of stutter within selected tetranucleotide and pentanucleotide repeat loci. The figure is a plot of the variability in percent stutter observed in a 13 different tetranucleotide and 5 different pentanucleotide repeat loci. The boxes represent the average percent stutter and the solid bars the range of stutter observed for each locus.

[0034] FIG. 5. Results of screening of tetranucleotide repeat markers for frequency of microsatellite instability. The figure is a plot of the number of microsatellite loci, out of a total of 273 markers, that displays a given percent MSI. For example, approximately 15 loci were altered in 100% of MSI-H tumor samples evaluated.

[0035] FIG. 6. Results of screening of pentanucleotide repeat markers for frequency of microsatellite instability. The figure is a plot of the percent MSI observed for each of
eight different tetranucleotide repeat loci in a set of nine MSI-H and a set of 30 MSS tumors.

**FIG. 7.** Microsatellite instability analysis using MONO-15 marker. The figure is a plot generated from capillary electrophoresis products of amplification of the MONO-15 locus of DNA from four different sets of paired normal and tumor samples originating from four different individuals.

**FIG. 8.** Percent MSI in 59 colon cancer samples using nine-locus MSI multiplex. The figure is a plot of the percent MSI observed in 59 colon cancer samples (29 MSH and 30 MSI-L or MSS samples) using the nine locus MSI multiplex described in Example 6, below (i.e., D18S518, D3S2432, D7S1808, D7S3046, D7S9070, D10S1426, BAT-25, BAT-26, and MONO-15).

**FIG. 9.** Fluorescent multiplex microsatellite analysis using a nine-locus MSI Multiplex. The figure is a plot generated from capillary electrophoresis of products of multiplex amplification of normal non-cancerous human genomic, using the nine locus MSI multiplex used in FIG. 8.

**FIG. 10.** Detection of microsatellite instability in colon cancer samples using a nine-locus MSI multiplex. The figure is a plot generated from capillary electrophoresis of products of multiplex amplification of DNA from paired normal and colon tumor sample, using the nine locus MSI multiplex used in FIG. 8.

**FIG. 11.** Detection of microsatellite instability in colon cancer samples using nine-locus MSI multiplex is the same type of plot shown in FIG. 10, generated using a different sample of paired normal and cancer DNA from a different individual.

**FIG. 12.** Detection of microsatellite instability in stomach cancer samples using nine-locus MSI multiplex. The figure is a plot generated from capillary electrophoresis of products of multiplex amplification of DNA from paired normal and stomach cancer tumor samples, using the nine locus MSI multiplex described in FIG. 8.

**FIG. 13.** Microsatellite analysis of paraffin embedded tissues with nine-locus MSI multiplex. The figure is a plot generated from capillary electrophoresis of products of multiplex amplification of DNA from paraffin embedded tissue, using the nine locus MSI multiplex described in FIG. 8.

**FIG. 14.** Percent MSI in colon cancer samples at 10 different microsatellite loci. The figure is a bar graph of the percent MSI observed in 66 colon cancer samples (36 MSI-H and 30 MSI-L stable or MSI-L samples) using a nine loci contained in the MSI multiplex described in Example 8 (i.e., BAT-26, D7S3070, D7S3046, BAT-40, MONO-15, D7S1808, BAT-25, D10S1426 and D3S2432) and D15S518.

**FIG. 15.** Fluorescent multiplex microsatellite analysis using a nine-locus MSI Multiplex. The figure is a plot generated from capillary electrophoresis of products of multiplex amplification of normal non-cancerous human genomic DNA, using the nine-locus MSI multiplex described in Example 8 labeled with primers labeled with fluorescent dyes, as follows. Primers to BAT-26, D7S3070, and D7S3046 were labeled with fluorescein; primers to BAT-40, MONO-15 and D7S1808 were labeled with JOE; and primers to BAT-25, D10S1426 and D3S2432 were labeled with TMR.

**FIG. 16.** Detection of microsatellite instability in colon cancer samples using a nine-locus MSI multiplex. The figure is a plot generated from capillary electrophoresis of products of multiplex amplification of DNA from paired normal and colon tumor samples, using the nine locus MSI multiplex and labeled primers used in FIG. 15.
one (1) to five (5), most preferably one (1) to four (4) base pairs in length. Each sequence repeated at least once within a microsatellite locus is referred to herein as a “repeat unit.” Each microsatellite locus preferably includes at least seven repeat units, more preferably at least ten repeat units, and most preferably at least twenty repeat units.

[0054] “Microsatellite Instability” (hereinafter, “MSI”), as used herein, refers to a form of genetic instability in which alleles of genomic DNA obtained from certain tissue, cells, or bodily fluids of a given subject change in length at a microsatellite locus. Specifically, MSI can be observed upon amplification of two different samples of genomic DNA from a particular subject, such as DNA from healthy and cancerous tissue, wherein the normal sample produces amplified alleles of one or two different lengths and the tumor sample produces amplified alleles wherein at least one of the alleles is of a different length from the amplified alleles of the normal sample of DNA at that locus. MSI generally appears as a result of the insertion or deletion of at least one repeat unit at a microsatellite locus.

[0055] “MSI-H”, as used herein, is a term used to classify tumors as having a high frequency of MSI. When five microsatellite loci are analyzed, such as the five microsatellite loci of the selected by a workshop on HNPPC at the National Cancer Institute in 1998 for use in the detection of HNPPC, a tumor is classified as MSI-H when at least five of the loci show instability (Boland, 1998). When more than five microsatellite loci are analyzed, a tumor is classified as MSI-H when at least 30% of the microsatellite loci of genomic DNA originating from the tumor is found to be unstable.

[0056] “MSI-L”, as used herein, is a term used to classify tumors as having a low frequency of MSI. When five microsatellite loci are analyzed, such as the five microsatellite loci of the selected by a workshop on HNPPC at the National Cancer Institute in 1998 for use in the detection of HNPPC, a tumor is classified as MSI-L when less than 30% of the microsatellite loci of genomic DNA originating from the tumor is found to be unstable. MSI-L tumors are thought to represent a distinct mutator phenotype with potentially different molecular etiology than MSI-H tumors (Thibodeau, 1998; Wu et al., 1999, Am J Hum Genetics 65:1291-1298). To accurately distinguish MSI-H and MSI-L phenotypes it has been recommended that more than five microsatellite markers be analyzed (Boland, 1998, supra.; Frazer et al., 1999 Oncology Research 6:497-505).

[0057] “MSS”, as used herein, refers to tumors which are microsatellite stable. When no microsatellite loci exhibit instability. The distinction between MSI-L and MSS can also only be accomplished when a significantly greater number of markers than five are utilized. The National Cancer Institute recommended use of an additional 19 mono- and dinucleotide repeat loci for this purpose, and for the purpose of making clearer distinctions between MSI-H and MSI-L tumors, as described above (Boland, 1998, supra).

[0058] “MSI-L-S”, as used herein, refers to all classified as either MSI-L or MSS.

[0059] “Microsatellite marker”, as used herein, refers to a fragment of genomic DNA which includes a microsatellite repeat and nucleic acid sequences flanking the repeat region.

[0060] “Monomorphic”, as used herein, refers to a locus of genomic DNA where only one allele pattern has been found to be present in the normal genomic DNA of all members of a population.

[0061] “Nucleotide”, as used herein, refers to a basic unit of a DNA molecule, which includes one unit of a phosphatidyl back bone and one of four bases, adenine (“A”); thymine (“T”); guanine (“G”); and cytosine (“C”).

[0062] “Polymerase chain reaction” or “PCR”, as used herein, refers to a technique in which cycles of denaturation, annealing with primer, and extension with DNA polymerase are used to amplify the number of copies of a target DNA sequence by approximately 10^9 times or more. The polymerase chain reaction process for amplifying nucleic acid is covered by U. S. Pat. Nos. 4.683.195 and 4.683.202, which are incorporated herein by reference for a description of the process.

[0063] “Primer”, as used herein, refers to a single-stranded oligonucleotide or DNA fragment which hybridizes with a strand of a locus of target DNA in such a manner that the 3’ terminus of the primer may act as a site of polymerization using a DNA polymerase enzyme.

[0064] “Primer pair”, as used herein, refers to a pair of primers which hybridize to opposite strands a target DNA molecule, to regions of the target DNA which flank a nucleotide sequence to be amplified.

[0065] “Primer site”, as used herein, refers to the area of the target DNA to which a primer hybridizes.

[0066] “Quasi-monomorphic”, as used herein, refers to a locus of genomic DNA where only one allele pattern has been found to be present in the normal genomic DNA of almost all the members of a population.

[0067] “Stutter”, as used herein, refers to a minor fragment observed after amplification of a microsatellite locus, one or more repeat unit lengths smaller than the predominant fragment or allele. It is believed to result from a DNA polymerase slippage event during the amplification process (Lewinson & Gutman, 1987 Molecular Biology Evolution 4:203; Schlotterer and Tautz, 1992 Nucleic Acids Research 20:21 1).

[0068] B. Selection of Loci to be Amplified or Co-Amplified:

[0069] At least one MSI locus amplified or co-amplified in each of the embodiments of the present invention illustrated and discussed herein is a mononucleotide repeat locus. Such loci have been shown to be very susceptible to alteration in tumors with dysfunctional DNA mismatch repair systems (Parsons, 1995 supra), making such loci particularly useful for the detection of cancer and other diseases associated with dysfunctional DNA mismatch repair systems. One group of researchers reported that by amplifying and analyzing a single mononucleotide repeat locus, BAT-26, they were able to correctly confirm the MSI-H status of 159 out of 160 (99.4% accuracy) tumor samples (Huang et al., 1997 Cancer Research 57:300-303).

[0070] Some mononucleotide repeat loci, including BAT-26, have also been identified as having quasi-monomorphic properties. Monomorphic or quasi-monomorphic properties make the comparison of normal/tumor pairs simpler, since
PCR products from normal samples are generally all the same size and any alterations in tumor samples are easily identified.

[0071] The principal draw-back to using a mononucleotide repeat locus in the analysis of genomic DNA is that amplification of any such locus results in a large number of extraneous amplified fragments of DNA of various lengths, the product of “stutter” during the amplification reaction. Such artifacts are present to a lesser degree in the products of amplifying loci with increasingly longer repeat units. For an illustration of the relationship between repeat unit length and the presence of extraneous amplified fragments, see FIG. 2. FIG. 2 shows increased stutter artifacts with decreasing repeat unit length from pentanucleotide to mononucleotide repeat loci.

[0072] When a mononucleotide locus is monomorphic or quasi-monomorphic, however, one can readily detect shifts in the size of an allele, indicating MSI, even in the presence of a high degree of stutter. When a locus is quasi-monomorphic, detection of shifts in size can be done by comparison of amplified alleles from genomic DNA from biological material of an individual, such as tumor tissue or bodily fluids, suspected of exhibiting microsatellite instability to the most commonly observed allele size at that locus in a population. This feature enables one to use a single standard or panel of standard allele patterns to analyze individual results, minimizing the amount of samples which must be taken from an individual in order to detect microsatellite instability in certain genomic DNA of the individual.

[0073] At least one of the microsatellite loci amplified in the method or using the kit of the present invention is preferably a mononucleotide repeat locus, more preferably a quasi-monomorphic mononucleotide repeat locus. The mononucleotide repeat locus selected for use in the methods and kits of the present invention is preferably unstable in cancerous biological material, but not in normal biological material. BAT-25, BAT-26 and BAT-40 have been identified as mononucleotide repeat loci useful in the identification of MSI in colorectal tumors characteristic of Hereditary Non-polyposis Colon Cancer (Zhou et al., 1998 Genes, Chromosomes & Cancer 21:101-107; Boland et al., 1998 Cancer Research 58:5248-5257; Dietmaier et al., 1997 Cancer Research 57:4749-4756; Hoang et al., 1997 Cancer Research 57:300-303). Two additional loci, identified herein as MONO-11 and MONO-15 were identified through a search of a public computerized database of sequence information (GenBank), and found to have the preferred characteristics for such loci, identified above. The search for and identification of mononucleotide repeat loci suitable for use in the present invention is illustrated in Example 2. Similar techniques could be used to identify other mononucleotide repeat loci suitable for use in the methods and kits of the present invention.

[0074] The mononucleotide repeat loci amplified or co-amplified according to the present methods or using the present kits are preferably quasi-monomorphic and exhibit instability in the type of tissue of interest for a given application. MONO-11 and MONO-15, BAT-25, and particularly BAT-26 are all quasi-monomorphic mononucleotide and exhibit instability in several cancerous tumor tissues. All four quasi-monomorphic mononucleotide repeat loci have been found to be particularly useful in the methods and kits of the present invention. BAT-40 has also been found to be useful in the methods and kits of the present invention, due to its instability in several cancerous tumor tissues. However, BAT-40 is not a quasi-monomorphic locus. At least one, more preferably at least two mononucleotide repeat microsatellite loci are co-amplified or co-amplified in the method of the present invention.

[0075] At least one mononucleotide repeat locus and at least two tetranucleotide repeat loci are co-amplified and analyzed according to at least some embodiments of the method and kits of the present invention. Tetranucleotide repeat loci inherently generate very few stutter artifacts when amplified, compared to microsatellite loci with shorter repeat units, particularly compared to mononucleotide repeat loci. (See, e.g., FIG. 2.) Such artifacts can be difficult to distinguish from MSI if a shifted allele occurs at the stutter position of the second allele. Therefore, concerns about interpretation, and the need for quasi-monomorphism in order to make data interpretation possible is not present, as it is for mononucleotide repeat loci. In fact, one can even use tetranucleotide repeat loci which are highly polymorphic in a population, provided it is stable within an individual subject. Such loci are commonly used in DNA typing.

[0076] As with any locus to be amplified in any method or using any kit of the present invention, the tetranucleotide repeat loci are preferably selected on the basis of being stable in the DNA of an individual except in the type of biological material of interest. Preferred tetranucleotide repeat loci used in the methods and kits of the present invention include: FGA, D1S518, D1S47, D1S1677, D2S1790, D3S2432, D5S818, D5S249, D6S1053, D7S3046, D7S1808, D7S3070, D8S1179, D10S1426, D10S2470, D12S391, D17S1294, D17S1299, and D18S51.

[0077] Additional mononucleotide or tetranucleotide loci with the same preferred criteria described above are preferably co-amplified with the set of at least three microsatellite loci described above. However, it is contemplated that microsatellite loci other than mononucleotide repeat or tetranucleotide repeat loci could be included in the set of at least three microsatellite loci co-amplified and analyzed according to the method or using the kit of the present invention.

[0078] Preferred methods for selection of loci and sets of loci amplified and analyzed according to the methods or using the kits of the present invention are discussed further, herein below. However, once the method and materials of this invention are disclosed, additional methods of selecting loci, primer pairs, and amplification techniques for use in the method and kit of this invention are likely to be suggested to one skilled in the art. All such methods are intended to be within the scope of the appended claims.

[0079] C. Additional Screening of Loci

[0080] When the method or kit of the present invention is to be used in clinical diagnostic assays to be used to determine treatment and prognosis of disease, it must be designed to produce results which are highly accurate (low false negatives) and specific (low false positive rate). Informative microsatellite loci are preferably identified by screening, more preferably by very extensive screening (see Examples 1 and 2). However, even the most informative microsatellite loci are not 100% sensitive and 100% specific.
The power of individual markers at detecting the presence of MSI in tissue associated with a particular disease, such as cancerous tumors, can be increased tremendously by multiplexing multiple markers. Increased information yielded from amplifying and analyzing greater numbers of loci results in increased confidence and accuracy in interpreting test results. To obtain needed sensitivity in detecting or diagnosing diseases such as cancer, it has been recommended that one analyze five or more highly informative microsatellite loci (Boland, 1998 Cancer Research 58: 5248-5257). Multiplexing of microsatellite loci further simplifies MSI analysis by allowing simultaneous amplification and analysis of all multiple loci, while reducing the amount of often-limited DNA required for amplification.

Another common problem in MSI determination relates to the occurrence of an intermediate MSI phenotype where only a small percentage (~30%) of microsatellite markers are altered in tumors (Boland, 1998, supra). These MSI-low tumors are thought to represent a distinct mutator phenotype with potentially different molecular etiology than MSI-H tumors (Thibodeau et al., 1993 Science 260: 816-8; Wu et al., 1999 Am J Hum Genetics 65: 1291-1298; Kolodner et al., 1999 Cancer Research 59: 5068-5074; Wijnen et al., 1999 Nature Genetics 23:142-144). It is not clear however if there is a real difference between MSI-L and MSS tumors. For purposes of diagnosis, MSI-L and MSS tumors are generally considered as one stable phenotypic class. To accurately distinguish MSI-H and MSI-L phenotypes it has been recommended that multiple microsatellite markers be analyzed (Boland, 1998; Frazer, 1999 supra).

It is contemplated that when the loci are to be co-amplified and analyzed in a multiplex amplification reaction, additional factors are taken into account, including ease and accuracy of interpretation of data. One of the primary factors affecting accurate data interpretation is the amount of stutter that occurs at microsatellite loci during PCR. Tetranucleotide repeat loci were chosen for inclusion in the MSI multiplex analyzed according to the method and using the kit of the present invention because they display considerably less stutter that shorter repeat types like dinucleotides (Fig. 2). However, careful selection of loci is still necessary in choosing low stutter loci because % stutter can vary considerably even within a particular repeat type (Fig. 4). Mononucleotide repeat loci were chosen for individual analysis and for inclusion in the MSI Multiplex because of high rates of instability in diseased biological material of interest.

Incidence of LOH is another factor in the selection of MSI loci to be amplified and analyzed in the methods or kits of the present invention. LOH can result in misidentification of a missing normal allele at a microsatellite marker as an indication of MSI when no other novel fragments are present for that marker. Specifically, one cannot easily discern whether this represents true LOH or MSI in which the shifted allele has co-migrated with the remaining wild-type allele. In order to minimize the problem described above, the microsatellite markers selected for use in the present methods and kits preferably exhibit a low frequency of LOH, preferably no more than about 20% LOH, more preferably no more than about 14% LOH, even more preferably, no more than about 3% LOH.

It is a relatively uncommon occurrence for a microsatellite marker to possess all necessary attributes described above (i.e., high sensitivity, high specificity, low stutter, low LOH). The threshold for an MSI analysis system to be used in a diagnostic test is even higher, requiring robust and reproducible results from multiple loci in one assay using small quantities of DNA from difficult samples and be able to distinguish between MSI-L and MSI-H phenotypes. All the specific preferred mono- and tetranucleotide repeat loci identified herein above as being preferred for use in the present invention were found to meet each of the criteria for MSI loci suitable for use in diagnostic analysis, set forth herein above.

Additional loci selection criteria particular to the two principal types of MSI loci amplified in the preferred multiplex analysis methods and using the kits of the present loci are described below.

D. Design of Primers

Primers for one or more microsatellite loci are provided in each embodiment of the method and kit of the present invention. At least one primer is provided for each locus, more preferably at least two primers for each locus, with at least two primers being in the form of a primer pair which flanks the locus. When the primers are to be used in a multiplex amplification reaction it is preferable to select primers and amplification conditions which generate amplified alleles from multiple co-amplified loci which do not overlap in size or, if they do overlap in size, are labeled in a way which enables one to differentiate between the overlapping alleles.

Primers suitable for the amplification of individual loci preferably co-amplified according to the methods of the present invention are provided in Example 4, Table 9, herein below. Primers suitable for use in one preferred multiplex of nine loci (i.e., BAT-25, D10S1426, D3S2432, BAT-26, D7S3046, D7S3070, MONO-15, D18S518, and D7S1808) are described in Example 6, Table 11. Primers suitable for use in a more preferred multiplex of nine loci (i.e., BAT-25, D10S1426, D3S2432, BAT-26, D7S3046, D7S3070, MONO-15, BAT-40, and D7S1808) are described in Example 8, Table 13. Guidance for designing these and other multiplexes is provided, below. It is contemplated that other primers suitable for amplifying the same loci or other sets of loci falling within the scope of the present invention could be determined by one of ordinary skill in the art.

E. Design and Testing of MSI Multiplex

The method of multiplex analysis of microsatellite loci of the present invention contemplates selecting an appropriate set of loci, primers, and amplification protocols to generate amplified alleles from multiple co-amplified loci which preferably do not overlap in size or, more preferably, which are labeled in a way which enables one to differentiate between the alleles from different loci which overlap in size. Combinations of loci may be rejected for either of the above two reasons, or because, in combination, one or more of the loci do not produce adequate product yield, or fragments which do not represent authentic alleles are produced in this reaction.

The following factors are preferably taken into consideration in deciding upon which loci to include in a multiplex of the present invention. To effectively design the microsatellite multiplex, size ranges for alleles at each locus are determined. This information is used to facilitate sepa-
ration of alleles between all the different loci, since any overlap could result in an allele from one locus being inappropriately identified as instability at another locus.

[0093] The amount of stutter exhibited by non-mononucleotide repeat loci is also preferably taken into consideration; as the amount of stutter exhibited by a locus can be a major factor in the ease and accuracy of interpretation of data. It is preferable to conduct a population study to determine the level of stutter present for each non-mononucleotide repeat locus. As noted above, tetranucleotide repeat markers display considerably less stutter that shorter repeat types like dinucleotides and therefore can be accurately scored in MSI assays (FIGS. 2 and 3)(Bacher & Schumm, 1998 Profiles in DNA 2(2):3-6). Note that even within a class of microsatellite loci, such as tetra- and pentanucleotide repeat loci, known to exhibit low stutter, the percent stutter can vary considerably within the repeat type (FIG. 3; see also FIG. 2) (Micka et al., 1999, supra).

[0094] Although at least one mononucleotide and at least two tetranucleotide repeat loci are included in the multiplex of MSI loci co-amplified according to the method or using the kit of the present invention, additional mononucleotide and/or tetranucleotide repeat loci can be included in the multiplex. It is also contemplated that multisatellite loci other than mono- or tetranucleotide repeat loci meeting the same or similar criteria to the criteria described above would be included in the multiplex.

[0095] The multiplex analyzed according to the present invention preferably includes a set of at least three MSI loci. It more preferably includes a set of at least five MSI loci, even more preferably a set of at least nine MSI loci. When the multiplex is a set of at least nine loci, it is preferably a set of at least the following loci: BAT-25, D10S1426, D3S2432, BAT-26, D7S046, D7S070, MONO-15, D1S518, and D7S1808, or more preferably a set of at least the following loci: BAT-25, D10S1426, D3S2432, BAT-26, D7S046, D7S070, BAT-40, MONO-15 and D7S1808. A list of primers suitable for use in the first multiplex is provided in Table 11 of Example 6, below. A list of primers suitable for use in the second, more preferred multiplex is provided in Table 13 of Example 8, below.

[0096] It is also contemplated that other factors, such as successful combinations of materials and methods, are taken into consideration in designing a multiplex of MSI loci. Determination of such additional factors can be determined by following the selection methods and guidelines disclosed herein, and by using techniques known to one of ordinary skill in the art of the present invention. Specifically, the same or substantially similar techniques can be used to identify the preferred MSI loci and sets of MSI loci described herein below to select primer pair sequences, and to adjust primer concentrations to identify an equilibrium in which all included loci may be amplified. In other words, once the method and materials of this invention are disclosed, various methods of selecting loci, primer pairs, and amplification techniques for use in the method and kit of this invention are likely to be suggested to one skilled in the art. All such methods are intended to be within the scope of the present claims.

[0097] F. Sources of Genomic DNA

[0098] The genomic DNA amplified or co-amplified according to the methods of the present invention originates from biological material from an individual subject, preferably a mammal, more preferably from a dog, cat, horse, sheep, mouse, rat, rabbit, monkey, or human, even more preferably from a human or a mouse, and most preferably from a human being. The biological material can be any tissue, cells, or biological fluid from the subject which contains genomic DNA. The biological material is preferably selected from the group consisting of tumor tissue, disseminated cells, feces, blood cells, blood plasma, serum, lymph nodes, urine, and other bodily fluids.

[0099] The biological material can be in the form of tissue samples fixed in formalin and embedded in paraffin (hereinafter “PET”). Tissue samples from biopsies are commonly stored in PET for long term preservation. Formalin creates cross-linkages within the tissue sample which can be difficult to break, sometimes resulting in low DNA yields. Another problem associated with formalin-fixed paraffin-embedded samples is amplification of longer fragments is often problematic. When DNA from such samples is used in multiplex amplification reactions, a significant decrease in peak heights is seen with increasing fragment size. The microsatellite analysis method and kit of the present invention are preferably designed to amplify and analyze DNA from PET tissue samples. (See Example 7 for an illustration of amplification of such samples using a method of the present invention.)

[0100] When the method or kit of the present invention is used in the analysis or detection of tumors, at least one sample of genomic DNA analyzed originates from a tumor. When a monomorphic or quasi-monomorphic locus, such as MONO-11 or MONO-15 is amplified, the size of the resulting amplified alleles can be compared to the most commonly observed allele size at that locus in the general population. The present method and kit is preferably used to diagnose or detect tumors by co-amplifying at least two different samples of DNA from the same individual, wherein one of the two samples originates from normal non-cancerous biological material.

[0101] The present invention is further explained by the following examples which should not be construed by way of limiting the scope of the present invention.

EXAMPLE 1

[0102] Screening Microsatellite Markers for Frequency of MSI

[0103] In this example, microsatellite markers in DNA isolated from tumors were compared to microsatellite markers in DNA isolated from normal tissue or cells in order to detect MSI. Specifically, microsatellite loci were amplified from paired normal/tumor DNA samples and genotyped. If one or more different alleles were present in the tumor DNA sample that were not found in normal sample from the same individual, then it was scored as MSI positive. Dinucleotide, tetranucleotide and pentanucleotide repeat microsatellite markers were analyzed for frequency of alteration to determine the relative sensitivity of particular markers to MSI. Detailed information about the specific procedures used in this example are provided herein, below.

[0104] Tissues and DNA isolation. Matched normal (blood) and neoplastic tissue samples for 39 patients were obtained from the Cooperative Human Tissue Network
(hereinafter, “CHTN”)(Ohio State University, Columbus, Ohio). After surgical resection, tissue samples were frozen in liquid nitrogen and stored at −70°C. Blood samples were collected by venipuncture using vacuum tubes. DNA extraction from blood and solid tissues was performed either by standard Phenol/chloroform method (Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Press, Cold Springs Harbor, N.Y.) or with QIAamp Blood and Tissue Kit (QIAGEN, Santa Clarita, Calif.) following manufacturer’s protocol.

[0105] PCR and Microsatellite Analysis. Fluorescently labeled primers from 275 microsatellite loci were used to amplify template DNA from normal/tumor pairs of samples. Two hundred and forty-five tetranucleotide repeat markers from the Research Genetics CHILC/Weber Human Screening Set Version 9.0 were evaluated (Research Genetics, Huntsville, Ala.). Additional primer sets for tetranucleotide and pentanucleotide repeat markers were obtained from Promega Corporation (Madison, Wis.) (PowerPlex™ 16 System contains D3S1358, TH01, D21S11, D18S51, Penta E, D5S818, D13S317, D7S820, D16S539, CSF1PO, Penta D, vWA, D8S1179, TPOX, and FGA loci). Pentanucleotide repeat markers TP53, Penta A, Penta B, Penta C, Penta D, Penta E, Penta F and Penta G or were custom synthesized (Promega Corporation, Madison, Wis.) using sequence data from public databases Minisatellite markers included for comparison purposes (D8S254, NM23, D18S35, D5S346, TP53-dl, D2S123, D1S2883, D3S1611, D7S501) were obtained from PE Biosystems (now doing business as Applied Biosystems Group, Foster City, Calif.).

[0106] Markers from Research Genetics, Human Screening Set Version 9.0, were multiplexed and screened for MSI using 2.5 ng of DNA in 10 μl PCR reactions described below. Other loci were evaluated as monoplexes using 1 ng DNA in 25 μl PCR reactions as described below. All markers were PCR amplified under the same conditions in using a Perkin-Elmer® GeneAmp PCR System 9600 Thermal Cycler, except as indicated otherwise below. Microsatellite markers from the PowerPlex™ 16 System (Technical Manual #TMD012, Promega Corporation, Madison, Wis.) and dinucleotide repeat markers from the Microsatellite RER Assay system (see product literature from PE Biosystems, non Applied Biosystems, Foster City, Calif.) were analyzed following manufacturer’s protocol.

### TABLE 1

<table>
<thead>
<tr>
<th>PCR Master Mix Component</th>
<th>Volume Per Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclease Free Water</td>
<td>3.30 μl</td>
</tr>
<tr>
<td>10X GoldST★R Buffer</td>
<td>3.00 μl</td>
</tr>
<tr>
<td>Primer 1</td>
<td>0.50 μl</td>
</tr>
<tr>
<td>Primer 2</td>
<td>0.50 μl</td>
</tr>
<tr>
<td>Primer 3</td>
<td>0.50 μl</td>
</tr>
<tr>
<td>Primer 4</td>
<td>0.50 μl</td>
</tr>
<tr>
<td>Primer 5</td>
<td>0.50 μl</td>
</tr>
<tr>
<td>Primer 6</td>
<td>0.50 μl</td>
</tr>
<tr>
<td>Amp/Taq Gold DNA Polymerase (5 Units/μl) (Perkin Elmer)</td>
<td>0.15 μl</td>
</tr>
<tr>
<td>DNA (1 ng/μl)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>Total Reaction Volume</td>
<td>10.00 μl</td>
</tr>
</tbody>
</table>

[0107] Table 2

<table>
<thead>
<tr>
<th>PCR Master Mix Component</th>
<th>Volume Per Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclease Free Water</td>
<td>17.45 μl</td>
</tr>
<tr>
<td>GoldST★R 10X Buffer</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>10X Primer Mix (10 μM)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>Amp/Taq Gold DNA Polymerase (5 Units/μl) (Perkin Elmer)</td>
<td>0.05 μl</td>
</tr>
<tr>
<td>Template DNA (0.4 μg/μl)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>Total Reaction Volume</td>
<td>25.00 μl</td>
</tr>
</tbody>
</table>

[0108] Table 3

<table>
<thead>
<tr>
<th>Cycling profile for PE 9600 Thermal Cycler</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 cycle 95°C for 11 minutes</td>
</tr>
<tr>
<td>1 cycle 96°C for 1 minute</td>
</tr>
<tr>
<td>10 cycles 94°C for 30 seconds</td>
</tr>
<tr>
<td>ramp 68 seconds to 50°C, hold for 30 seconds ramp 50 seconds to 70°C, hold for 45 seconds</td>
</tr>
<tr>
<td>20 cycles 94°C for 30 seconds</td>
</tr>
<tr>
<td>ramp 60 seconds to 50°C, hold for 30 seconds ramp 50 seconds to 70°C, hold for 45 seconds</td>
</tr>
<tr>
<td>1 cycle 60°C for 30 minutes</td>
</tr>
<tr>
<td>1 cycle Soak 4°C</td>
</tr>
</tbody>
</table>

[0109] One microliter of PCR product (Research Genetics markers were first diluted 1:4 in 1x GoldST★R PCR buffer) was combined with 1 μl of Internal Lane Standard (Promega Corporation, Madison, Wis.) and 24 μl deionized formamide. Samples were denatured by heating at 95°C for 3 minutes and immediately chilled on ice for 3 minutes. Separation and detection of amplified fragments was performed on an ABI PRISM® 310 Genetic Analyzer following the standard protocol recommended in the User’s Manual with the following settings: 5 second Injection Time, 15 kV Injection Voltage, 15 kV Run Voltage, 60°C Run Temperature, and 28 minute Run Time.

[0110] Assay Interpretation. Identification of normal and tumor allele sizes was accomplished by examining the appropriate electropherogram from the ABI PRISM 310 Genetic Analyzer (Applied Biosystems) and determining the predominant peaks for each locus. One or two peaks or alleles can be present for each locus in normal samples depending upon whether individual is homozygous or heterozygous for a particular marker. Allelic patterns or genotypes for normal and tumor pairs were compared and scored as MSI positive if one or more different alleles were present in the tumor DNA samples that were not found in normal sample from the same individual.

[0111] A wide range in frequency of alteration was observed in between samples and between markers evaluated. Samples were divided into two groups based on the frequency of alteration using guidelines recommended in NCI Workshop on MSI (Boland et al., 1998). Samples with greater than 30-40% of markers exhibiting alteration in tumor samples were classified as MSI-H and ≤30-40% as MSI-L. Samples with no alterations were classified as mic-
rosatellite stable (MSS). Based on this definition of MSI phenotypes, nine samples were classified as MSI-H and the remaining 30 as either MSI-L or MSS.

**EXAMPLE 2**

**[0113]** Identification and Characterization of Mononucleotide Repeat Loci

**[0114]** Due to the highly informative nature of mononucleotide repeat loci in determining MSI phenotype, we also investigated poly (A) regions of the human genome as a new source of markers for MSI assays. To accomplish this, mononucleotide repeats were identified from GenBank (http://www.ncbi.nlm.nih.gov/) using BLASTN (Altschul, et al. 1990 J. Mol. Biol. 215:402-410) searches for (A)\(_n\) or (T)\(_n\) sequences. The (A)\(_n\) sequence was added to eliminate frequent mRNA sites and to ensure that flanking sequence was available for designing primers for PCR. Next, flanking primers were designed for 33 GenBank DNA sequences using Oligo Primer Analysis Software version 6.0 (National Biosciences, Inc., Plymouth, Minn.) to amplify the region containing the poly (A) repeat. Evaluation of loci was performed using 9 MSI-H and 30 MSS colon cancer samples and corresponding normal DNA samples. Protocols for PCR, detection and analysis are described in Example 1.

**[0115]** Two characteristics were screened for in the new loci. First, loci were screened for which could detect MSI in the MSI-H group and not in the MSS group. Second, loci were selected on the basis of being monomorphic or nearly monomorphic (quasi-monomorphic). The monomorphic nature of the new loci was determined by genotyping 96 samples from 5 racial groups (African-American, Asian-American, Caucasiam-American, Hispanic-American, Indian-American). Screening of 33 mononucleotide repeat loci revealed four new mononucleotide repeat loci (MONO-3, MONO-11, MONO-15, and MONO-19) that displayed high sensitivity to MSI (Table 4 and FIG. 7) and were relatively homozygous and monomorphic (Table 5). The degree of homozygosity and monomorphism detected at each such locus is shown on Table 5.

**TABLE 4**

<table>
<thead>
<tr>
<th>MS Type</th>
<th>BAT-25</th>
<th>BAT-26</th>
<th>MONO-3</th>
<th>MONO-11</th>
<th>MONO-15</th>
<th>MONO-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSI-H</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>MSI-L or MSS</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

**EXAMPLE 3**

**[0116]**

**TABLE 5**

| Polymorphism Level of Mononucleotide Repeat Loci |
|--------------------------|--------------------------|
| BAT-25       | BAT-26       | MONO-11      | MONO-15      |
| % Homo-zygosity | % Homo-zygosity | % Homo-zygosity | % Homo-zygosity |
| 95% (82/86)   | 95% (89/94)   | 89% (76/85)   | 99% (87/88)   |

**[0117]** Population Studies

**[0118]** A population study was conducted in which 93 samples from African-American individuals were genotyped using preferred microsatellite markers selected as candidates for multiplexing in the studies illustrated in Examples 1 and 2, above. See Table 6, below, and Table 3, above, for the amplification conditions used. See Table 7, below, for a list of the loci amplified and analyzed in this study. In addition, a pooled Human Diversity DNA sample and control CEPH DNAs 1331-1 and 1331-2 (Coriell Cell Repository, Camden, N.J.) were included in the screening population. African-American samples were used because they contain the greatest genetic diversity found in all racial groups.

**[0119]** To facilitate screening of 96 samples with 22 different microsatellite markers, selected markers were multiplexed in small groups of three. Multiplexed primer sets were used to amplify individual sample DNAs using conditions described below.

**TABLE 6**

<table>
<thead>
<tr>
<th>PCR Master Mix Component</th>
<th>Volume Per Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclease Free Water</td>
<td>17.50 μl</td>
</tr>
<tr>
<td>GoldSt☆R 10X Buffer (Promega)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>1X Triplex Primer Mix (1 to 10 μM each)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>AmpliTaq Gold DNA Polymerase (5 Unit/μl)</td>
<td>0.20 μl</td>
</tr>
<tr>
<td>(Perkin Elmer)</td>
<td></td>
</tr>
<tr>
<td>Template DNA (0.4 ng/μl)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>Total Reaction Volume</td>
<td>25.00 μl</td>
</tr>
</tbody>
</table>

**[0120]** The results of the population study are summarized in Table 7. The size of the smallest and largest allele for each locus was identified to determine allele size range. To calculate percent stutter, the peak height of the stutter band was divided by the peak height generated by the true allele,
then multiplied by 100. Minimum and maximum stutter values were calculated for each locus as well as the combined average percent stutter from 20 random samples.

<table>
<thead>
<tr>
<th>Locus</th>
<th>GenBank ID #</th>
<th>Allele Size Range</th>
<th>Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAT-25</td>
<td>U68384</td>
<td>18 bp</td>
<td>42 bp</td>
</tr>
<tr>
<td>BAT-26</td>
<td>U41210</td>
<td>18 bp</td>
<td>12 bp</td>
</tr>
<tr>
<td>MONO-11</td>
<td>AC007684</td>
<td>ND</td>
<td>14 bp</td>
</tr>
<tr>
<td>MONO-18</td>
<td>AC007684</td>
<td>ND</td>
<td>6 bp</td>
</tr>
<tr>
<td>D1S547</td>
<td>G07828</td>
<td>46 bp</td>
<td>26 bp</td>
</tr>
<tr>
<td>D1S518</td>
<td>G07854</td>
<td>48 bp</td>
<td>ND</td>
</tr>
<tr>
<td>D1S1677</td>
<td>G09926</td>
<td>40 bp</td>
<td>35 bp</td>
</tr>
<tr>
<td>D2S1790</td>
<td>G08190</td>
<td>68 bp</td>
<td>44 bp</td>
</tr>
<tr>
<td>D3S232</td>
<td>G08240</td>
<td>67 bp</td>
<td>40 bp</td>
</tr>
<tr>
<td>D5S818</td>
<td>G08446</td>
<td>36 bp</td>
<td>ND</td>
</tr>
<tr>
<td>D5S2649</td>
<td>G15752</td>
<td>40 bp</td>
<td>37 bp</td>
</tr>
<tr>
<td>D6S1053</td>
<td>G08556</td>
<td>48 bp</td>
<td>36 bp</td>
</tr>
<tr>
<td>D7S1808</td>
<td>G08683</td>
<td>58 bp</td>
<td>44 bp</td>
</tr>
<tr>
<td>D7S8046</td>
<td>G15353</td>
<td>48 bp</td>
<td>71 bp</td>
</tr>
<tr>
<td>D7S8070</td>
<td>G27340</td>
<td>44 bp</td>
<td>44 bp</td>
</tr>
<tr>
<td>D8S1179</td>
<td>G08710</td>
<td>44 bp</td>
<td>ND</td>
</tr>
<tr>
<td>D9S2169</td>
<td>G08748</td>
<td>12 bp</td>
<td>ND</td>
</tr>
<tr>
<td>D10S677</td>
<td>G12433</td>
<td>28 bp</td>
<td>40 bp</td>
</tr>
<tr>
<td>D10S1426</td>
<td>G08812</td>
<td>28 bp</td>
<td>ND</td>
</tr>
<tr>
<td>D11S2470</td>
<td>G12286</td>
<td>48 bp</td>
<td>29 bp</td>
</tr>
<tr>
<td>D12S391</td>
<td>G08921</td>
<td>52 bp</td>
<td>48 bp</td>
</tr>
<tr>
<td>D17S1294</td>
<td>G07967</td>
<td>44 bp</td>
<td>28 bp</td>
</tr>
<tr>
<td>D17S1299</td>
<td>G07952</td>
<td>40 bp</td>
<td>ND</td>
</tr>
<tr>
<td>D18S51</td>
<td>L18333</td>
<td>76 bp</td>
<td>ND</td>
</tr>
<tr>
<td>FGA</td>
<td>M64982</td>
<td>120 bp</td>
<td>ND</td>
</tr>
</tbody>
</table>

**EXAMPLE 4**

- **[0121]** MSI Multiplex Design
- **[0122]** In order to develop a multiplex MSI assay system which is highly sensitive to MSI, with minimal stutter, and minimal incidence of LOH, the criteria listed in Table 8, below, were used to screen loci identified in the Examples above as possible candidates for use in MSI analysis:

<table>
<thead>
<tr>
<th>Locus</th>
<th>Repeat Type</th>
<th>GenBank Accession No.</th>
<th>Primer SEQ. ID</th>
<th>% MSI (MSH-I)</th>
<th>% LOH (MSH-I)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAT-25</td>
<td>Mono</td>
<td>U68384</td>
<td>1, 2</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>BAT-26</td>
<td>Mono</td>
<td>U41210</td>
<td>3, 4</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>MONO-11</td>
<td>Mono</td>
<td>AC007684</td>
<td>5, 6</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>MONO-18</td>
<td>Mono</td>
<td>AC007684</td>
<td>7, 8</td>
<td>100%</td>
<td>0%</td>
</tr>
<tr>
<td>D1S1677</td>
<td>Tetra</td>
<td>G07854</td>
<td>9, 10</td>
<td>80%</td>
<td>0%</td>
</tr>
<tr>
<td>D1S547</td>
<td>Tetra</td>
<td>G07828</td>
<td>31, 12</td>
<td>80%</td>
<td>3%</td>
</tr>
<tr>
<td>D1S1677</td>
<td>Tetra</td>
<td>G09926</td>
<td>13, 14</td>
<td>80%</td>
<td>3%</td>
</tr>
<tr>
<td>D2S1790</td>
<td>Tetra</td>
<td>G08190</td>
<td>15, 16</td>
<td>82%</td>
<td>3%</td>
</tr>
<tr>
<td>D3S232</td>
<td>Tetra</td>
<td>G08240</td>
<td>17, 18</td>
<td>83%</td>
<td>3%</td>
</tr>
<tr>
<td>D5S818</td>
<td>Tetra</td>
<td>G08446</td>
<td>19, 20</td>
<td>72%</td>
<td>14%</td>
</tr>
<tr>
<td>D5S2649</td>
<td>Tetra</td>
<td>G15752</td>
<td>21, 22</td>
<td>76%</td>
<td>7%</td>
</tr>
<tr>
<td>D6S1053</td>
<td>Tetra</td>
<td>G08556</td>
<td>23, 24</td>
<td>76%</td>
<td>0%</td>
</tr>
<tr>
<td>D7S8046</td>
<td>Tetra</td>
<td>G08683</td>
<td>25, 26</td>
<td>90%</td>
<td>0%</td>
</tr>
<tr>
<td>D7S8070</td>
<td>Tetra</td>
<td>G10353</td>
<td>27, 28</td>
<td>93%</td>
<td>0%</td>
</tr>
<tr>
<td>D8S2649</td>
<td>Tetra</td>
<td>G15752</td>
<td>21, 22</td>
<td>76%</td>
<td>7%</td>
</tr>
<tr>
<td>D8S2169</td>
<td>Tetra</td>
<td>G08710</td>
<td>31, 32</td>
<td>75%</td>
<td>7%</td>
</tr>
<tr>
<td>D9S2169</td>
<td>Tetra</td>
<td>G08748</td>
<td>33, 34</td>
<td>72%</td>
<td>3%</td>
</tr>
<tr>
<td>D10S1426</td>
<td>Tetra</td>
<td>G08812</td>
<td>35, 36</td>
<td>86%</td>
<td>3%</td>
</tr>
<tr>
<td>D10S2470</td>
<td>Tetra</td>
<td>G01205</td>
<td>37, 38</td>
<td>83%</td>
<td>3%</td>
</tr>
<tr>
<td>D12S391</td>
<td>Tetra</td>
<td>G08921</td>
<td>39, 40</td>
<td>79%</td>
<td>3%</td>
</tr>
<tr>
<td>D17S1294</td>
<td>Tetra</td>
<td>G07967</td>
<td>41, 42</td>
<td>88%</td>
<td>3%</td>
</tr>
<tr>
<td>D17S1299</td>
<td>Tetra</td>
<td>G07952</td>
<td>43, 44</td>
<td>79%</td>
<td>3%</td>
</tr>
<tr>
<td>D18S51</td>
<td>Tetra</td>
<td>L18333</td>
<td>45, 46</td>
<td>75%</td>
<td>7%</td>
</tr>
<tr>
<td>FGA</td>
<td>Tetra</td>
<td>M64982</td>
<td>47, 48</td>
<td>83%</td>
<td>7%</td>
</tr>
</tbody>
</table>

**[0123]** | *MSH-I samples: N = 29 and MSH-I/L samples N = 30.*
EXAMPLE 5

[0124] Analysis of Mismatch Repair Genes

[0125] In order to determine the underlying cause of MSI in MSI-H tumor samples used in developing the Multiplex MSI Assay, protein expression levels for MLH1 and MSH2 genes were examined. Immunohistochemical analysis of paraffin-embedded tissues from eight MSI-H samples was performed as described in Thibodeau et al. (Cancer Research 58, 1713-1718). Lack of protein expression in MLH1 and MSH2 genes is expected in tumor samples exhibiting high levels of MSI and is an indication of dysfunctional mismatch repair system.

[0126] The results of the immunohistochemical assays on the MSI-H tumor samples is shown in Table 10. Note that an “ND” in a protein expression column in Table 10 indicates that nothing was detected.

<table>
<thead>
<tr>
<th>Tumor Sample</th>
<th>Source</th>
<th>PhenoType</th>
<th>MLH1</th>
<th>MSH2</th>
</tr>
</thead>
<tbody>
<tr>
<td>C172</td>
<td>CHTN</td>
<td>MSI-H</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>C404</td>
<td>CHTN</td>
<td>MSI-H</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>C507</td>
<td>CHTN</td>
<td>MSI-H</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>C546</td>
<td>CHTN</td>
<td>MSI-H</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>C624</td>
<td>CHTN</td>
<td>MSI-H</td>
<td>-</td>
<td>ND</td>
</tr>
<tr>
<td>C710</td>
<td>CHTN</td>
<td>MSI-H</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>C1166</td>
<td>CHTN</td>
<td>MSI-H</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>C5412</td>
<td>CHTN</td>
<td>MSI-H</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>S15945</td>
<td>CHTN</td>
<td>MSI-H</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>A-1</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>A-5</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>A-7</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>A-15</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>A-19</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>A-29</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>A-49</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>A-50</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>A-73</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>A-102</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-2</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-52</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-61</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-75</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-76</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-93</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-107</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-155</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-164</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-166</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-173</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-199</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-209</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-210</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-268</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-299</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-334</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-379</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-402</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>B-564</td>
<td>Mayo Clinic</td>
<td>MSI-H</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

EXAMPLE 6

[0127] MSI Multiplex Assay Development and Validation

[0128] Once the best loci were selected for use in designing multiplexes to be analyzed according to the methods of the present invention, problems associated with multiplex PCR and incompatibility between loci needed to be overcome. This required careful primer design and extensive trial and error to find loci that were capable of simultaneous amplification using a single set of PCR conditions. Problems encountered included: (1) primer-primer interactions that occurred when large number of oligos were combined in a single PCR reaction, (2) primer design limitations due to sequence constraints at a particular locus (e.g., minimum size of amplicon allowed by DNA sequence, sub-optimal %GC of primers, difficulty balancing Tm's for all primers under uniform PCR conditions, difficulty in finding primers with desirable thermal profiles to minimize non-specific amplification, hairpin formation and self dimerization of primers, homology to other repeat sequences in human genome), and (3) multiplex design allowing separation of all 9 loci within limited size range of 250 bp.

[0129] Based on extensive evaluation of close to 300 microsatellite markers described in Examples 1 through 5, nine loci were selected for the preferred MSI Multiplex Assay (Table 11). Three loci are monoplex repeats (BAI-25, BA1-26 and MONO-15) and six were tetranucleotide repeats (D1S518, D3S2432, D7S5046, D10S1426, D7S5070, D7S1808). These loci were found to be an excellent set of markers for identifying MSI in tumor samples. Results of MSI analysis on 29 MSI-H and 30 MSI-L or MSS colon cancer samples using this nine-locus multiplex are summarized in FIG. 8.

[0130] A typical example of results produced from use of the nine loci MSI Multiplex described above is shown in FIG. 9. The image was generated by simultaneous amplifying all nine selected microsatellite loci followed by separation of PCR products on an ABI 310 CE. Separation of all nine microsatellite loci in a single capillary (or gel lane) was accomplished by designing the multiplex so that loci would not overlap in size or through use of different fluorescent dyes. The size ranges for the different multiplex loci were determined by genotyping 93 samples from African-American individuals using MSI Multiplex described following protocol described below. In addition, a pooled Human Diversity DNA sample and control CEPH DNAs 1331-1 and 1331-2 (CORIELL Cell Repository) were included in the screening population. African-American samples were used because they contain the greatest amount of genetic diversity found in all racial groups.
TABLE 11  
MSI Multiplex Assay Loci and Primers  

<table>
<thead>
<tr>
<th>Locus</th>
<th>GenBank ID No.</th>
<th>Repeat Type</th>
<th>Dye</th>
<th>Size Range</th>
<th>Primer 1 (SEQ.ID.)</th>
<th>Primer 2 (SEQ.ID.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAT25</td>
<td>U63834</td>
<td>Mono</td>
<td>TMR</td>
<td>115-127</td>
<td>1</td>
<td>60</td>
</tr>
<tr>
<td>D1S1612</td>
<td>G08813</td>
<td>Tetra</td>
<td>TMR</td>
<td>152-173</td>
<td>57</td>
<td>59</td>
</tr>
<tr>
<td>D1S232</td>
<td>G08240</td>
<td>Tetra</td>
<td>TMR</td>
<td>198-234</td>
<td>17</td>
<td>59</td>
</tr>
<tr>
<td>BAT26</td>
<td>U412120</td>
<td>Mono</td>
<td>FL</td>
<td>103-116</td>
<td>61</td>
<td>62</td>
</tr>
<tr>
<td>D7S3046</td>
<td>G10353</td>
<td>Tetra</td>
<td>FL</td>
<td>122-163</td>
<td>55</td>
<td>56</td>
</tr>
<tr>
<td>D7S570</td>
<td>G25246</td>
<td>Tetra</td>
<td>FL</td>
<td>186-249</td>
<td>53</td>
<td>54</td>
</tr>
<tr>
<td>MONO15</td>
<td>AC007364</td>
<td>Mono</td>
<td>JOE</td>
<td>115-117</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>D13S318</td>
<td>G07854</td>
<td>Tetra</td>
<td>JOE</td>
<td>136-178</td>
<td>49</td>
<td>50</td>
</tr>
<tr>
<td>D7S1808</td>
<td>G08643</td>
<td>Tetra</td>
<td>JOE</td>
<td>190-218</td>
<td>51</td>
<td>52</td>
</tr>
</tbody>
</table>

[0131] Protocol for MSI Multiplex Assay. Template DNA from normal and tumor tissues obtained from the same individual were purified using QIAamp Blood and Tissue Kit (Qiagen, Santa Clarita, Calif.) following manufacturers protocol. Two nanograms of template DNA in a 25 μl reaction volume was PCR amplified using protocol detailed in Table 12, below, using the cycling profile described in Table 3, above.

TABLE 12  
Amplification Mix for MSI Multiplex Assay  

<table>
<thead>
<tr>
<th>PCR Master Mix Component</th>
<th>Volume Per Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclease Free Water</td>
<td>17.00 μl</td>
</tr>
<tr>
<td>Goldstar 10X Buffer (Promega)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>Primer Pair Mix (30 μM)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>AmpliTag Gold DNA Polymerase</td>
<td>0.50 μl</td>
</tr>
<tr>
<td>(Perkin Elmer)</td>
<td></td>
</tr>
<tr>
<td>Template DNA (0.8 ng/μl)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>Total Reaction Volume</td>
<td>25.00 μl</td>
</tr>
</tbody>
</table>

[0132] One microliter of PCR product was combined with 1 μl of Internal Lane Standard (Promega Corporation, Madison, Wis.) and 24 μl deionized formamide. Samples were denatured by heating at 95°C for 3 minutes and immediately chilled on ice for 3 minutes. Separation and detection of amplified fragments was performed on an ABI PRISM 310 Genetic Analyzer following the standard protocol recommended in the User’s Manual with the following settings:

| Run Module: | GS STR POP4 (Filler set A) |
| Injection Time: | 4 seconds |
| Injection Voltage: | 35 kV |
| Run Voltage: | 35 kV |
| Run Temperature: | 60°C |
| Run Time: | 24 minutes |

[0133] Identification of normal and tumor allele amplicon sizes was accomplished by examining the appropriated electropherogram from the ABI PRISM 310 Genetic Analyzer and determining the predominant peaks for each locus. One or two peaks or alleles were present for each locus in normal samples depending upon whether individual was homozygous or heterozygous for a particular marker. Allelic patterns or genotypes for normal and tumor pairs were compared and scored as MSI positive if one or more different alleles were present in the tumor DNA samples that were not found in normal sample from the same individual. Typical examples of results obtained using multiplex designed for MSI analysis are shown in FIGS. 10 and 11 for colon cancer and FIG. 12 for stomach cancer.

EXAMPLE 7

[0134] Amplification of DNA from PET Samples using MSI Multiplex

[0135] Microsatellite loci from the multiplex identified in Example 6, above, were evaluated for their ability to amplify DNA from formalin-fixed paraffin-embedded samples. DNA was extracted from three 10 micron sections cut from PET blocks using QIAamp Tissue Kit (Qiagen, Santa Clarita, Calif.) according to the manufacturer’s instructions with the following modifications: One hundred microliters of QIAGEN AE buffer preheated to 70°C was added to block, incubated for 5 minutes, centrifuged, then reapplied to block for second elution. Two microliters (out of 100μl) of purified DNA solution was used as template for PCR reactions. The nine locus multiplexed primer set described in Example 6 was used to amplify DNA from PET samples. The results indicate that the MSI Multiplex is capable of amplifying DNA from difficult and commonly used PET samples (FIG. 13).

EXAMPLE 8

[0136] Second MSI Multiplex System Configuration

[0137] A second set of nine loci was identified for analysis in a second MSI multiplex assay system, from eight of the best known set of loci identified in Example 4, above, for determining MSI in colon tumor samples, and from an additional mononucleotide repeat locus (BAT-40). Design of the multiplex loci was such that loci would not overlap in size within a single capillary or gel lane or could be labeled using different dyes when separated and overlap would occur. Using empirically determined optimal experimental conditions, multiplex microsatellite analysis was performed on several hundred healthy individuals.

[0138] The set of nine loci selected for the MSI Multiplex Assay and relevant identifying data for each locus is shown in Table 13, below.
TABLE 13

<table>
<thead>
<tr>
<th>Locus</th>
<th>GenBank ID No.</th>
<th>Repeat Type</th>
<th>Dye</th>
<th>Size Range (SEQ. ID.)</th>
<th>Primer 1 (SEQ. ID.)</th>
<th>Primer 2 (SEQ. ID.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAT-25</td>
<td>U63683</td>
<td>Mono</td>
<td>TMR</td>
<td>118-127</td>
<td>1</td>
<td>60</td>
</tr>
<tr>
<td>D16S1426</td>
<td>G08982</td>
<td>Tetra</td>
<td>TMR</td>
<td>152-173</td>
<td>57</td>
<td>59</td>
</tr>
<tr>
<td>D3S232</td>
<td>G08240</td>
<td>Tetra</td>
<td>TMR</td>
<td>198-234</td>
<td>63</td>
<td>59</td>
</tr>
<tr>
<td>BAT-26</td>
<td>U41210</td>
<td>Mono</td>
<td>FL</td>
<td>103-116</td>
<td>61</td>
<td>62</td>
</tr>
<tr>
<td>D7S3046</td>
<td>G03533</td>
<td>Tetra</td>
<td>FL</td>
<td>122-163</td>
<td>55</td>
<td>64</td>
</tr>
<tr>
<td>D7S3070</td>
<td>G27346</td>
<td>Tetra</td>
<td>FL</td>
<td>186-249</td>
<td>53</td>
<td>54</td>
</tr>
<tr>
<td>BAT-40</td>
<td>M35180</td>
<td>Mono</td>
<td>JOE</td>
<td>81-105</td>
<td>65</td>
<td>66</td>
</tr>
<tr>
<td>MONO-15</td>
<td>AC007984</td>
<td>Mono</td>
<td>JOE</td>
<td>145-155</td>
<td>67</td>
<td>68</td>
</tr>
<tr>
<td>D7S1808</td>
<td>G00643</td>
<td>Tetra</td>
<td>JOE</td>
<td>190-218</td>
<td>51</td>
<td>52</td>
</tr>
</tbody>
</table>

[0139] Four of the loci in the second MSI multiplex are mononucleotide repeats (BAT-25, BAT-26, BAT-40 and MONO-15) and five are tetranucleotide repeats (D3S232, D7S1808, D7S3046, D7S3070, D16S1426). Table 13 shows primer pairs used to amplify each locus in the second MSI multiplex, and approximate size range of fragments produced upon amplification of each locus with each primer pair. The primer sequences identified in Table 13 were selected as being particularly suitable for amplification of each locus in the second MSI multiplex.

[0140] Results of MSI analysis on 36 MSI-H and 30 MSS colon cancer samples using the nine-locus multiplex and primer pairs described in Table 13 is shown in Table 14, below, and in FIG. 14. FIG. 14 is a bar graph showing percent MSI measured at each locus of the multiplex from each of the two types of samples studied (i.e., MSI-H and MSS). An additional locus from the multiplex identified in Example 6, i.e. D1S518, was also included in this assay.

TABLE 14

<table>
<thead>
<tr>
<th>Locus</th>
<th>% MSI-H</th>
<th>% MSS</th>
</tr>
</thead>
<tbody>
<tr>
<td>D1S518</td>
<td>75</td>
<td>5</td>
</tr>
<tr>
<td>BAT-25</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>D16S1426</td>
<td>86</td>
<td>7</td>
</tr>
<tr>
<td>D3S232</td>
<td>86</td>
<td>3</td>
</tr>
<tr>
<td>BAT-40</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>MONO-15</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>D7S308</td>
<td>94</td>
<td>0</td>
</tr>
<tr>
<td>BAT-26</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>D7S3070</td>
<td>86</td>
<td>5</td>
</tr>
<tr>
<td>D7S3046</td>
<td>76</td>
<td>7</td>
</tr>
</tbody>
</table>

[0141] The results of the assay, summarized in Table 14 and illustrated in FIG. 14, showed that amplification of BAT-40 resulted in clearer discrimination between MSI-H and MSS samples than D1S518. All nine loci amplified using the second MSI multiplex system were detected with very high efficiency.

EXAMPLE 9

[0142] MSI Multiplex System Analysis

[0143] Ninety-three samples from African-American individuals, a pooled Human Diversity DNA sample and control DNA from cell lines 1331-1 and 1331-2 (Coriell Cell Repository, Camden N.J.) were examined using the nine multiplex loci system described in Example 8. The simultaneous amplification of all nine selected microsatellite loci followed by separation of products on an ABI 310 CE, as illustrated below, produced all expected products.

[0144] Protocol for MSI Multiplex Assay. Two nanograms of normal template DNA were purified using QIAamp Blood and Tissue Kit (QIAGEN, Santa Clarita, Calif.) following the manufactures protocol. DNA was amplified by PCR in a 25 μl reaction volume using protocol detailed in Table 15 and in Table 16, below.

TABLE 15

<table>
<thead>
<tr>
<th>Amplification Mix for MSI Multiplex Assay</th>
<th>Volume Per Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR Master Mix Component</td>
<td></td>
</tr>
<tr>
<td>Nuclease Free Water</td>
<td>17.00 μl</td>
</tr>
<tr>
<td>GoldStikit&lt;sup&gt;®&lt;/sup&gt; 10X Buffer (Promega)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>Primer Pair Mix (10 μM)</td>
<td>2.50 μl</td>
</tr>
<tr>
<td>AmpliTaq Gold DNA Polymerase (Perkin Elmer)</td>
<td>0.50 μl</td>
</tr>
<tr>
<td>Template DNA (0.8 ng/μl)</td>
<td>2.80 μl</td>
</tr>
<tr>
<td>Total Reaction Volume</td>
<td>25.00 μl</td>
</tr>
</tbody>
</table>

TABLE 16

| Cycling profile for MSI Multiplex Assay |
|----------------------------------------|----------------|
| 1 cycle 95° C. for 11 minutes          |                |
| 1 cycle 96° C. for 1 minute            |                |
| 10 cycles 94° C. for 30 seconds        |                |
| ramp 68 seconds to 60° C. hold for 30 seconds |                |
| ramp 50 seconds to 70° C. hold for 90 seconds |                |
| 20 cycles 94° C. for 30 seconds        |                |
| ramp 60 seconds to 60° C. hold for 30 seconds |                |
| ramp 50 seconds to 70° C. hold for 90 seconds |                |
| 1 cycle 60° C. for 30 minutes          |                |
| 1 cycle 60° C. for 30 minutes          |                |
| Soak 4° C.                             |                |

[0145] One microliter of PCR product was combined with 1 μl of Internal Lane Standard (DG2611, Promega Corporation, Madison, Wis.) and 24 μl deionized formamide. Samples were denatured by heating at 95° C. for 3 minutes and immediately chilled on ice for 3 minutes. Separation and detection of amplified fragments was performed on an ABI PRISM 310 Genetic Analyzer following the standard protocol recommended in the User’s Manual with the following settings:
Identification of normal allele amplicon sizes was accomplished by examining the appropriate electropherogram from the ABI PRISM 310 Genetic Analyzer and determining the predominant peaks for each locus. These results are shown in FIG. 15. One or two peaks or alleles were present for each locus in normal samples depending upon whether individual was homozygous or heterozygous for a particular marker.

EXAMPLE 10

MSI Multiplex System Analysis on Patient Samples

Allelic patterns or genotypes for paired normal and tumor tissues from the same individual were examined using the multiplex loci described in Example 8, above. The simultaneous amplification of all nine selected microsatellite loci followed by separation of products on an ABI 310 CE showed all expected products.

The protocol for the Multiplex MSI assay and the Cycling profile for the Patient samples were conducted exactly as in Example 9, above. Identification of normal and tumor allele amplicon sizes was accomplished by examining the electropherogram from the ABI PRISM 310 Genetic Analyzer and determining the predominant peaks for each locus.

Typical results of the paired tissue examples are shown in FIG. 16. One or two alleles were present for each locus in normal samples depending upon whether individual was homozygous or heterozygous for a particular marker. Allelic patterns or genotypes for normal and tumor pairs were compared and scored as MSI positive if one or more different alleles were present in the tumor DNA samples that were not found in normal sample from the same individual.

While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various modifications, including variations, additions, and omissions that may be made in what has been described. Accordingly, it is intended that these modifications also be encompassed by the present invention and that the scope of the present invention be limited solely by the broadest interpretation that lawfully can be accorded the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 68

<210> SEQ ID NO 1
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BAT-25 primer
<400> SEQUENCE: 1
tccctcctcctgattgagt 20

<210> SEQ ID NO 2
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BAT-25 primer
<400> SEQUENCE: 2
ttcagctcctgattgacgtc 21

<210> SEQ ID NO 3
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BAT-26 primer
<400> SEQUENCE: 3
tgacttcttcctggacgtc 21
<210> SEQ ID NO 4
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BAT-26 primer

<400> SEQUENCE: 4

accattcas catttttacac cc 22

<210> SEQ ID NO 5
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: MONO-11 primer

<400> SEQUENCE: 5

gagctgtgat tgcaactacac 20

<210> SEQ ID NO 6
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: MONO-15 primer

<400> SEQUENCE: 6

ggcatgcaatt actactgtcc tacc 24

<210> SEQ ID NO 7
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: MONO-15 primer

<400> SEQUENCE: 7

tcagatttat ttggtgacct actc 24

<210> SEQ ID NO 8
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: MONO-15 primer

<400> SEQUENCE: 8

ggccggagtc gcagtgag 18

<210> SEQ ID NO 9
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D16518 primer

<400> SEQUENCE: 9

tgcaagtctt ggcaactttc 20

<210> SEQ ID NO 10
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D16518 primer

<400> SEQUENCE: 10

tggagactgct ggcaactttc 20
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D1S518 primer

<400> SEQUENCE: 10

aaaaaagtg cggccacgctg

<210> SEQ ID NO 11
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D1S547 primer

<400> SEQUENCE: 11

ctgaagttgg aggattgctt

<210> SEQ ID NO 12
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D1S547 primer

<400> SEQUENCE: 12

aattcagggg agttccagag

<210> SEQ ID NO 13
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D1S1677 primer

<400> SEQUENCE: 13

agtcagcctg attgaccagg

<210> SEQ ID NO 14
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D1S1677 primer

<400> SEQUENCE: 14

cttaagtgta caggaagagc g

<210> SEQ ID NO 15
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D261790 primer

<400> SEQUENCE: 15

aatatgtcat tgtctagtcc

<210> SEQ ID NO 16
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D261790 primer
SEQUENCE: 16
gagttttatt ggcasaagca

SEQ ID NO 17 LENGTH 20 TYPE DNA ORGANISM: Homo sapiens FEATURE: OTHER INFORMATION: D3S2432 primer

SEQUENCE: 17
ggcagcaggg tagatagca

SEQ ID NO 18 LENGTH 23 TYPE DNA ORGANISM: Homo sapiens FEATURE: OTHER INFORMATION: D3S2432 primer

SEQUENCE: 18
acactaasac agcatagtca ggc

SEQ ID NO 19 LENGTH 20 TYPE DNA ORGANISM: Homo sapiens FEATURE: OTHER INFORMATION: D5S818 primer

SEQUENCE: 19
gggtatattt octottttgtt

SEQ ID NO 20 LENGTH 20 TYPE DNA ORGANISM: Homo sapiens FEATURE: OTHER INFORMATION: D5S818 primer

SEQUENCE: 20
tgattcoaat ctaagcaca

SEQ ID NO 21 LENGTH 20 TYPE DNA ORGANISM: Homo sapiens FEATURE: OTHER INFORMATION: D5S2849 primer

SEQUENCE: 21
cotggaagas ccaagtgotta

SEQ ID NO 22 LENGTH 20 TYPE DNA ORGANISM: Homo sapiens FEATURE: OTHER INFORMATION: D5S2849 primer

SEQUENCE: 22
ttgagcogag aaatgttgtgag
<210> SEQ ID NO 23
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE: 
<223> OTHER INFORMATION: D6S1053 primer
<400> SEQUENCE: 23

tatttcaasg gcagcaasgc

<210> SEQ ID NO 24
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE: 
<223> OTHER INFORMATION: D6S1053 primer
<400> SEQUENCE: 24
gcttgcaagc agctatatgt

<210> SEQ ID NO 25
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE: 
<223> OTHER INFORMATION: D7S1808 primer
<400> SEQUENCE: 25
cagacaasac aatgqggqsg

<210> SEQ ID NO 26
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE: 
<223> OTHER INFORMATION: D7S1808 primer
<400> SEQUENCE: 26
cosaataaga atcagacagc

<210> SEQ ID NO 27
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE: 
<223> OTHER INFORMATION: D7S3046 primer
<400> SEQUENCE: 27
acatacgag gatacgatgg

<210> SEQ ID NO 28
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE: 
<223> OTHER INFORMATION: D7S3046 primer
<400> SEQUENCE: 28
tataactct cctcctatct ccc

<210> SEQ ID NO 29
<211> LENGTH: 20
<212> TYPE: DNA
<121> TYPE: DNA
<122> ORGANISM: Homo sapiens
<120> FEATURE:
<223> OTHER INFORMATION: D753070 primer
<400> SEQUENCE: 29
cccccaagt ttattctct
<210> SEQ ID NO 30
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<20> FEATURE:
<223> OTHER INFORMATION: D753070 primer
<400> SEQUENCE: 30
ggaagccaa tggtgacctg
<210> SEQ ID NO 31
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<20> FEATURE:
<223> OTHER INFORMATION: D851179 primer
<400> SEQUENCE: 31
ttttgtatt tcattgtat atcg
<210> SEQ ID NO 32
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<20> FEATURE:
<223> OTHER INFORMATION: D851179 primer
<400> SEQUENCE: 32
cgtgctata attagttctttc
<210> SEQ ID NO 33
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<20> FEATURE:
<223> OTHER INFORMATION: D952169 primer
<400> SEQUENCE: 33
ttccccaaag tgcctctcta
<210> SEQ ID NO 34
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<20> FEATURE:
<223> OTHER INFORMATION: D952169 primer
<400> SEQUENCE: 34
agcccccaat gttatgcaag
<210> SEQ ID NO 35
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<20> FEATURE:
<223> OTHER INFORMATION: D1061426 primer
<400> SEQUENCE: 35

```
ttggtggtg ctccctctttt
```

<210> SEQ ID NO 36
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D10S1426 primer

<400> SEQUENCE: 36
cctttaactgc atttgccgca

<210> SEQ ID NO 37
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D10S2470 primer

<400> SEQUENCE: 37
ccttaactgcctcagagtt

<210> SEQ ID NO 38
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D10S2470 primer

<400> SEQUENCE: 38
caggacagat ttcgctggt

<210> SEQ ID NO 39
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D12S391 primer

<400> SEQUENCE: 39
aacagatc atggatgcat

<210> SEQ ID NO 40
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D12S391 primer

<400> SEQUENCE: 40
ttcgctttag actgqagact

<210> SEQ ID NO 41
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D17S1294 primer

<400> SEQUENCE: 41
ttgcatgcagatggatgcat
<210> SEQ ID NO 42
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D1761294 primer

<400> SEQUENCE: 42

tttttcctcactaatgtttagaagacg

<210> SEQ ID NO 43
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D1761299 primer

<400> SEQUENCE: 43
tggcacttg gagaccattta

<210> SEQ ID NO 44
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D18551 primer

<400> SEQUENCE: 44
gagccattgg gacacacattg

<210> SEQ ID NO 45
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D18551 primer

<400> SEQUENCE: 45
caaaccogac taccagcaac

<210> SEQ ID NO 46
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: FGA primer

<400> SEQUENCE: 47
caataggttt taactacaca g

<210> SEQ ID NO 48
<211> LENGTH: 20
<212> TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: FGA primer
SEQUENCE: 48
ctttctcagt cctctgacac

SEQ ID NO: 49
LENGTH: 25
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: D1S510 primer
SEQUENCE: 49
gtcaatccct tgttataaaa ttata

SEQ ID NO: 50
LENGTH: 24
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: D1S510 primer
SEQUENCE: 50
attggcaact gcataggagt tctc

SEQ ID NO: 51
LENGTH: 24
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: D7S1808 primer
SEQUENCE: 51
ggaggaaag tcttaacagt gat

SEQ ID NO: 52
LENGTH: 24
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: D7S1808 primer
SEQUENCE: 52
atggccttg atgttgttgt tact

SEQ ID NO: 53
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: D7S3070 primer
SEQUENCE: 53
cattctctct gccoccatga

SEQ ID NO: 54
LENGTH: 26
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: D7S3070 primer
<400> SEQUENCE: 54
atttgcacgt tgaaaaaggtg cagatg

<210> SEQ ID NO 55
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D7S3046 primer

<400> SEQUENCE: 55
gaggagacag ccagggatat a

<210> SEQ ID NO 56
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D7S3046 primer

<400> SEQUENCE: 56
attttcatatat acctctctct cctatct

<210> SEQ ID NO 57
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D10S1426 primer

<400> SEQUENCE: 57
coccttggtgtgtctctct

<210> SEQ ID NO 58
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D10S1426 primer

<400> SEQUENCE: 58
atttgcacgt tgaaaaaggtg cagatg

<210> SEQ ID NO 59
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D3S2432 primer

<400> SEQUENCE: 59
attttgtcag cggagacaat acgc

<210> SEQ ID NO 60
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BAT-25 primer

<400> SEQUENCE: 60
atttgcagct ttaactatgg ctct
<210> SEQ ID NO 61
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BAT-26 primer
<400> SEQUENCE: 61

tgactcttt tgacttcgag caagt

<210> SEQ ID NO 62
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BAT-26 primer
<400> SEQUENCE: 62

aaccasctcas catttttasct ctt

<210> SEQ ID NO 63
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D7S82432 primer
<400> SEQUENCE: 63

gtttgcatgt gcacacgtca

<210> SEQ ID NO 64
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: D7S3046 primer
<400> SEQUENCE: 64

attttcatat tacocatctc cotctct

<210> SEQ ID NO 65
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BAT-40 primer
<400> SEQUENCE: 65

aaacacotgc ttttgttctc

<210> SEQ ID NO 66
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: BAT-40 primer
<400> SEQUENCE: 66

gtagcgaag acaaccttg

<210> SEQ ID NO 67
<211> LENGTH: 24
<212> TYPE: DNA
We claim:

1. A method of analyzing micro-satellite loci, comprising steps of:
   a) providing primers for co-amplifying a set of at least three microsatellite loci of genomic DNA, comprising at least one monomeric repeat locus selected from the group consisting of BAT-25, BAT-26, BAT-40, MONO-11, and MONO-15, and at least two tetrameric repeat loci selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2432, D5S818, D5S249, D6S1053, D7S1808, D7S2008, D8S1179, D9S2169, D10S1426, D11S240, D12S391, D13S1294, D17S1299, and D18S51;
   b) co-amplifying the set of at least three microsatellite loci from at least one sample of genomic DNA in a multiplex amplification reaction, using the primers, thereby producing amplified DNA fragments; and
   c) determining the size of the amplified DNA fragments.

2. The method of claim 1, wherein the genomic DNA is human genomic DNA.

3. The method of claim 1, wherein the set of at least three microsatellite loci is a set of at least five microsatellite loci, comprising two monomeric repeat loci selected from the group consisting of BAT-25, BAT-26, BAT-40, MONO-11, and MONO-15, and three tetrameric repeat loci selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2432, D5S818, D5S249, D6S1053, D7S1808, D7S2008, D8S1179, D9S2169, D10S1426, D11S240, D12S391, D13S1294, D17S1299, and D18S51.

4. The method of claim 1, wherein at least one of the primers provided in step (a) has a nucleic acid sequence selected from the group of primer sequences identified by: SEQ ID NO: 1-68.

5. The method of claim 1, wherein the set of at least three microsatellite loci is a set of at least nine microsatellite loci, comprising: BAT-25, BAT-26, MONO-15, BAT-40, D3S2432, D7S3046, D7S3070, D7S1808, and D10S1426.

6. The method of claim 5, wherein the set of at least nine microsatellite loci is co-amplified using at least one primer for each locus selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 60 when the locus is BAT-25,
   SEQ ID NO: 61 and SEQ ID NO: 62 when the locus is BAT-26,
   SEQ ID NO: 65 and SEQ ID NO: 66 when the locus is MONO-15,
   SEQ ID NO: 67 and SEQ ID NO: 68 when the locus is BAT-40,
   SEQ ID NO: 63 and SEQ ID NO: 59 when the locus is D3S2432,
   SEQ ID NO: 51 and SEQ ID NO: 52 when the locus is D7S1808,
   SEQ ID NO: 53 and SEQ ID NO: 54 when the locus is D7S3070,
   SEQ ID NO: 55 and SEQ ID NO: 64 when the locus is D7S3046, and
   SEQ ID NO: 57 and SEQ ID NO: 58 when the locus is D10S1426.

7. The method of claim 1, wherein the set of at least three microsatellite loci is co-amplified in step (c) using at least one oligonucleotide primer for each locus which is fluorescently labeled.

8. The method of claim 1, wherein the at least one sample of genomic DNA comprises the first sample of genomic DNA originating from normal non-cancerous biological material from an individual and a second sample of genomic DNA originating from a tumor of the individual, the method further comprising:
   detecting microsatellite instability by comparing the size of the amplified DNA fragments produced from co-amplifying the first sample of genomic DNA to the size of the amplified DNA fragments produced from co-amplifying the second sample of genomic DNA.

9. The method of claim 8, wherein the microsatellite instability results are used in prognostic tumor diagnosis.

10. The method of claim 8, wherein the microsatellite instability results are used in the diagnosis of familial tumor predisposition.
11. The method of claim 8, wherein the microsatellite instability results are used to detect cancerous tumors of the gastro-intestinal system and of the endometrium.

12. The method of claim 11 wherein the cancerous tumors are tumors from a colorectal cancer.

13. A method of detecting microsatellite instability in genomic DNA, comprising the steps of:

a) providing primers for co-amplifying a set of at least three microsatellite loci of genomic DNA, comprising at least one mononucleotide repeat locus selected from the group consisting of BAT-25, BAT-26, BAT-40, MONO-11, and MONO-15, and at least two tetranucleotide repeat loci selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2342, D5S818, D5S2849, D6S1053, D7S8046, D7S8048, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D17S1294, D17S1299, and D18S51;

b) co-amplifying the set of at least three microsatellite loci from a first sample of genomic DNA originating from normal non-cancerous biological material from an individual and a from a second sample of genomic DNA originating from a second biological material from the individual, in separate multiplex amplification reactions, using at least one oligonucleotide primer for each of the microsatellite loci, thereby producing first amplified DNA fragments from the first sample and second amplified DNA fragments from the second sample; and

c) comparing the size of first amplified DNA fragments to the size of the second amplified DNA fragments to detect instability in any of the at least three microsatellite loci of the second genomic DNA.

14. The method of claim 13, wherein the genomic DNA is human genomic DNA.

15. The method of claim 13, wherein the set of at least three microsatellite loci is a set of at least five microsatellite loci, comprising two mononucleotide repeat loci selected from the group consisting of BAT-25, BAT-26, BAT-40, MONO-11, and MONO-15, and three tetranucleotide repeat loci selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2342, D5S818, D5S2849, D6S1053, D7S8046, D7S8048, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D17S1294, D17S1299, and D18S51.

16. The method of claim 13, wherein at least one of the primers provided in step (a) has a nucleic acid sequence selected from the group of primer sequences identified by:

SEQ ID NO: 65 and SEQ ID NO: 66 when the locus is MONO-15,
SEQ ID NO: 67 and SEQ ID NO: 68 when the locus is BAT-40,
SEQ ID NO: 63 and SEQ ID NO: 59 when the locus is D3S2342,
SEQ ID NO: 51 and SEQ ID NO: 52 when the locus is D7S1808,
SEQ ID NO: 53 and SEQ ID NO: 54 when the locus is D7S3070,
SEQ ID NO: 55 and SEQ ID NO: 64 when the locus is D7S3046, and
SEQ ID NO: 57 and SEQ ID NO: 58 when the locus is D10S1426.

20. The method of claim 13, wherein the second sample of biological material is selected from the group consisting of: tumor tissue, disseminated cells, feces, blood cells, blood plasma, serum, lymph nodes, urine, and other bodily fluids.

21. The method of claim 13, wherein the microsatellite instability results are used in prognostic tumor diagnosis.

22. The method of claim 13, wherein the microsatellite instability results are used in the diagnosis of familial tumor predisposition.

23. The method of claim 13, wherein the microsatellite instability results are used to detect cancerous tumors of the gastro-intestinal system and of the endometrium.

24. The method of claim 23, wherein the cancerous tumors are tumors from a colorectal cancer.

25. A kit for analyzing microsatellite loci of genomic DNA, comprising:

a single container with oligonucleotide primers for co-amplifying a set of at least three microsatellite loci of genomic DNA, the set comprising one mononucleotide repeat locus selected from the group consisting of BAT-25, BAT-26, BAT-40, MONO-11, and MONO-15, and at least two tetranucleotide repeat locus selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2342, D5S818, D5S2849, D6S1053, D7S8046, D7S1808, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D17S1294, D17S1299, and D18S51.

26. The kit of claim 25, wherein the genomic DNA is human genomic DNA.

27. The kit of claim 25, wherein the set of at least three microsatellite loci is a set of at least five microsatellite loci, comprising two mononucleotide repeat loci selected from the group consisting of BAT-25, BAT-26, BAT-40, MONO-11, and MONO-15, and three tetranucleotide repeat loci selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2342, D5S818, D5S2849, D6S1053, D7S8046, D7S1808, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D17S1294, D17S1299, and D18S51.

28. The kit of claim 25, wherein the set of at least two microsatellite loci is a set of at least nine microsatellite loci, comprising: BAT-25, BAT-26, BAT-40, MONO-15, D3S2342, D7S1808, D7S3070, D7S3046, and D10S1426.

29. The kit of claim 28, wherein at least one of the oligonucleotide primers is selected from the group consisting of:
a) providing primers for co-amplifying a set of at least nine microsatellite loci of human genomic DNA, comprising BAT-25, BAT-26, MONO-15, BAT-40, D3S2432, D7S3046, D7S3070, D7S1808, and D10S1426;

b) co-amplifying the set of at least three microsatellite loci from at least one sample of genomic DNA in a multiplex amplification reaction, using the primers, thereby producing amplified DNA fragments; and

c) determining the size of the amplified DNA fragments.

35. The method of claim 33, wherein instability in the set of microsatellite loci co-amplified by the primers is an indication of tumors of the gastrointestinal system or of the endometrium.

36. The method of claim 25, wherein the microsatellite instability is an indication of colorectal cancer.

37. A method of analyzing microsatellite loci, comprising steps of:

a) providing primers for co-amplifying a set of at least nine microsatellite loci of human genomic DNA, comprising BAT-25, BAT-26, MONO-15, BAT-40, D3S2432, D7S3046, D7S3070, D7S1808, and D10S1426;
43. The method of claim 42, wherein the at least two tetra-nucleotide repeat loci are selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2342, D5S818, D5S2849, D6S1053, D7S3046, D7S1801, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D12S1294, D12S1299, and D18S51.

44. The method of claim 42, wherein the at least one mono-nucleotide repeat locus is selected from the group consisting of BAT-25, BAT-26, BAT-40, MONO-11, and MONO-15.

45. The method of claim 42, wherein the set of at least three microsatellite loci is a set of at least five microsatellite loci, comprising:

- at least two mono-nucleotide repeat loci selected from the group consisting of BAT-25, BAT-26, MONO-11, BAT-40, and MONO-15; and
- at least three tetra-nucleotide repeat loci selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2342, D5S818, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D12S1294, D17S1299, and D18S51.

46. The method of claim 42, wherein at least one of the primers provided in step (a) has a nucleic acid sequence selected from the group of primer sequences identified by:

SEQ ID NO: 1-68.

47. The method of claim 42, wherein the set of at least three microsatellite loci is a set of at least nine microsatellite loci, comprising BAT-25, BAT-26, MONO-15, D1S518, D3S2342, D7S1808, D7S3070, D7S3046, and D10S1426.

48. The method of claim 47, wherein the set of at least nine microsatellite loci is co-amplified using at least one primer for each locus selected from the group consisting of:

SEQ ID NO: 1 and SEQ ID NO: 60 when the locus is BAT-25,
SEQ ID NO: 61 and SEQ ID NO: 62 when the locus is BAT-26,
SEQ ID NO: 7 and SEQ ID NO: 8 when the locus is MONO-15,
SEQ ID NO: 49 and SEQ ID NO: 50 when the locus is D1S518,
SEQ ID NO: 17 and SEQ ID NO: 59 when the locus is D3S2342,
SEQ ID NO: 51 and SEQ ID NO: 52 when the locus is D7S1808,
SEQ ID NO: 53 and SEQ ID NO: 54 when the locus is D7S3070,
SEQ ID NO: 55 and SEQ ID NO: 56 when the locus is D7S3046, and
SEQ ID NO: 57 and SEQ ID NO: 58 when the locus is D10S1426.

49. The method of claim 42, wherein the set of at least three microsatellite loci is a set of at least nine microsatellite loci, comprising BAT-25, BAT-26, MONO-15, BAT-40, D3S2342, D7S3046, D7S3070, D7S1808, and D10S1426.

50. The method of claim 49, wherein the set of at least nine microsatellite loci is co-amplified using at least one primer for each locus selected from the group consisting of:

SEQ ID NO: 1 and SEQ ID NO: 60 when the locus is BAT-25,
SEQ ID NO: 61 and SEQ ID NO: 62 when the locus is BAT-26,
SEQ ID NO: 65 and SEQ ID NO: 66 when the locus is MONO-15,
SEQ ID NO: 67 and SEQ ID NO: 68 when the locus is BAT-40,
SEQ ID NO: 63 and SEQ ID NO: 59 when the locus is D3S2342,
SEQ ID NO: 51 and SEQ ID NO: 52 when the locus is D7S1808,
SEQ ID NO: 53 and SEQ ID NO: 54 when the locus is D7S3070,
SEQ ID NO: 55 and SEQ ID NO: 64 when the locus is D7S3046, and
SEQ ID NO: 57 and SEQ ID NO: 58 when the locus is D7S1426.

51. The method of claim 41, wherein the set of at least three microsatellite loci is co-amplified in step (e) using at least one oligonucleotide primer for each locus which is fluorescently labeled.

52. The method of claim 41, wherein the at least one sample of genomic DNA comprises a first sample of genomic DNA originating from normal non-cancerous biological material from an individual and a second sample of genomic DNA originating from a tumor of the individual; the method further comprising:

detecting microsatellite instability by comparing the size of the amplified DNA fragments produced from co-amplifying the first sample of genomic DNA to the size of the amplified DNA fragments produced from co-amplifying the second sample of genomic DNA.

53. The method of claim 52, wherein the microsatellite instability results are used in prognostic tumor diagnosis.

54. The method of claim 52, wherein the microsatellite instability results are used in the diagnosis of familial tumor predisposition.

55. The method of claim 52, wherein the microsatellite instability results are used to detect cancerous tumors of the gastro-intestinal system and of the endometrium.

56. The method of claim 55 wherein the cancerous tumors are tumors from a colorectal cancer.

57. A kit for analyzing microsatellite loci of human genomic DNA, comprising:

a single container with oligonucleotide primers for co-amplifying a set of at least three microsatellite loci of human genomic DNA, the set comprising one mono-nucleotide repeat locus and two tetra-nucleotide repeat loci.

58. The kit of claim 57, wherein the two tetra-nucleotide repeat loci are selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2342, D5S818, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D17S1294, D17S1299, and D18S51.

59. The kit of claim 57, wherein the mono-nucleotide repeat locus is selected from the group consisting of BAT-25, BAT-26, BAT-40, MONO-11, and MONO-15.
60. The kit of claim 57, wherein the set of at least three microsatellite loci is a set of at least five microsatellite loci, comprising two mono-nucleotide repeat loci selected from the group consisting of BAF-25, BAF-26, BAF-40, MONO-11, and MONO-15, and three tetra-nucleotide repeat loci selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2432, D5S818, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D8S1179, D9S2169, D10S1246, D10S2470, D12S391, D17S1294, D17S1299, and D18S51.

61. The kit of claim 57, wherein the set of at least two microsatellite loci is a set of at least nine microsatellite loci, comprising: BAF-25, BAF-26, MONO-15, D1S518, D3S2432, D7S1808, D7S3070, D7S3046, D10S1426.

62. The kit of claim 61, wherein at least one of the oligonucleotide primers is selected from the group consisting of:

SEQ ID NO: 1 and SEQ ID NO: 60 when the locus is BAF-25,
SEQ ID NO: 61 and SEQ ID NO: 62 when the locus is BAF-26,
SEQ ID NO: 7 and SEQ ID NO: 8 when the locus is MONO-15,
SEQ ID NO: 49 and SEQ ID NO: 50 when the locus is D1S518,
SEQ ID NO: 17 and SEQ ID NO: 19 when the locus is D3S2432,
SEQ ID NO: 51 and SEQ ID NO: 52 when the locus is D7S1808,
SEQ ID NO: 53 and SEQ ID NO: 54 when the locus is D7S3070,
SEQ ID NO: 55 and SEQ ID NO: 56 when the locus is D7S3046,
SEQ ID NO: 57 and SEQ ID NO: 58 when the locus is D10S1426.

63. The kit of claim 57, wherein the set of at least two microsatellite loci is a set of at least nine microsatellite loci, comprising: BAF-25, BAF-26, MONO-15, BAF-40, D3S2432, D7S3046, D7S3070, D7S1808, and D10S1426.

64. The kit of claim 63, wherein at least one of the oligonucleotide primers is selected from the group consisting of:

SEQ ID NO: 1 and SEQ ID NO: 60 when the locus is BAF-25,
SEQ ID NO: 61 and SEQ ID NO: 62 when the locus is BAF-26,
SEQ ID NO: 65 and SEQ ID NO: 66 when the locus is MONO-15,
SEQ ID NO: 67 and SEQ ID NO: 68 when the locus is BAF-40,
SEQ ID NO: 63 and SEQ ID NO: 59 when the locus is D3S2432,
SEQ ID NO: 51 and SEQ ID NO: 52 when the locus is D7S1808,
SEQ ID NO: 53 and SEQ ID NO: 54 when the locus is D7S3070,
SEQ ID NO: 55 and SEQ ID NO: 64 when the locus is D7S3046, and
SEQ ID NO: 57 and SEQ ID NO: 58 when the locus is D10S1426.

65. The kit of claim 57, wherein at least one oligonucleotide primer for each of the at least three microsatellite loci in the set is fluorescently labeled.

66. The kit of claim 57, wherein the kit further comprises a thermostable polymerase.

67. The kit of claim 57, wherein the kit further comprises first control DNA isolated from normal non-cancerous biological material, and second control DNA from biological material lacking mismatch repair genes.

68. The kit of claim 57, wherein instability in the set of microsatellite loci co-amplified by the primers can be used in prognostic tumor diagnosis.

69. The kit of claim 57, wherein instability in the set of microsatellite loci co-amplified by the primers can be used in the diagnosis of familial tumor predisposition.

70. The kit of claim 57, wherein instability in the set of microsatellite loci co-amplified by the primers is an indication of tumors of the gastrointestinal system or of the endometrium.

71. The kit of claim 70, wherein the microsatellite instability is an indication of colorectal cancer.

* * * * *